COMPOSITIONS CONTAINING TUMOR REJECTION ANTIGEN PRECURSORS OR TUMOR REJECTION ANTIGENS, AND AN ADJUVANT AND/OR GROWTH FACTOR

Abstract: Compositions with improved immunogenic effect are disclosed. The compositions contain one or more peptides which, when complexed with a cell surface molecule, such as an MHC, HLA or B cell receptor, provoke an immune response. The compositions contain adjuvants such as saponins, which potentiate the immune response. Especially preferred are compositions which stimulate cytolytic T cell responses, such as peptides which satisfy criteria for MHC binding, such as peptides derived from tumor rejection antigen precursors, including MAGE, BAGE, and GAGE derived peptides.

Description: COMPOSITIONS CONTAINING TUMOR REJECTION ANTIGEN PRECURSORS OR TUMOR REJECTION ANTIGENS, AND AN ADJUVANT AND/OR GROWTH FACTOR RELATED APPLICATIONS This application is a continuation in part of all of the following applications, each of which discuss the provocation of cytolytic T cells in the presence of complexing tumor rejection antigens and MHC/HLA molecules: PCT application PCT/US92/04354 (designating the United States); Serial No. 938,334, filed August 31, 1992; Serial No. 008,446, filed January 22, 1993; Serial No. 54,714, filed April 28, 1993; Serial No. 203,054, filed February 28, 1994; Serial No. 233,305, filed April 26, 1994; Serial No. 195,186, filed February 14, 1994; Serial No. 196,630, filed February 15, 1994; Serial No. 32,978, filed March 18, 1993; Serial Nos. 217,186; 217,187; and 217,188, all of which were filed on March 24, 1994; Serial No. 190,411, filed on April 1, 1994 and Serial No. 253,503, filed June 3, 1994. FTET-P OF THE INVEMTIQN This invention relates to compositions useful in the generation of an immune response against the classes of molecules referred to as tumor rejection antigen precursors ("TRAPs") and tumor rejection antigens ("TRAs"). The immune response includes, inter alia, the production of antibodies against the TRAPs and TRAs, as well as T cells specific for complexes of TRA and major histocompatibility molecules ("MHCs"). Such T cells and antibodies may be generated, e.g., in a mouse, rat, rabbit, sheep, goat or other non-human animal, and then used in diagnostic methods to identify tumor presence. The compositions may also be used, therapeutically, via administration to a subject afflicted with a cancerous condition or one where cell transformation has taken place, such as melanoma or dysplastic nevi, to provoke an immune response against tumors, cancer cells, and transformed cells. BACKGROUND AND PRIOR ART The study of the recognition or lack of recognition of cancer cells by a host organism has proceeded in many different directions. Understanding of the field presumes some understanding of both basic immunology and oncology. Early research on mouse tumors revealed that these displayed molecules which led to rejection of tumor cells when transplanted into syngeneic animals. These molecules are "recognized" by T-cells in the recipient animal, and provoke a cytolytic T-cell response with lysis of the transplanted cells. This evidence was first obtained with tumors induced in vitro by chemical carcinogens, such as methylcholanthrene. The antigens expressed by the tumors and which elicited the T- cell response were found to be different for each tumor. See Prehn, et al., J. Natl. Cane. Inst. 18: 769-778 (1957); Klein et al.. Cancer Res. 20: 1561-1572 (I960); Gross, Cancer Res. 3: 326-333 (1943), Basombrio, Cancer Res. 30: 2458-2462 (1970) for general teachings on inducing tumors with chemical carcinogens and differences in cell surface antigens. This class of antigens has come to be known as "tumor specific transplantation antigens" or "TSTAs". Following the observation of the presentation of such antigens when induced by chemical carcinogens, similar results were obtained when tumors were induced in vitro via ultraviolet radiation. See Kripke, J. Natl. Cane. Inst. 53: 333-1336 (1974). While T-cell mediated immune responses were observed for the types of tumor described supra. spontaneous tumors were thought to be generally non-immunogenic. These were therefore believed not to present antigens which provoked a response to the tumor in the tumor carrying subject. See Hewitt, et al., Brit. J. Cancer 33: 241-259 (1976). The family of turn " antigen presenting cell lines are immunogenic variants obtained by mutagenesis of mouse tumor cells or cell lines, as described by Boon et al., J. Exp. Med. 152: 1184-1193 (1980), the disclosure of which is incorporated by reference. To elaborate, tum " antigens are obtained by mutating tumor cells which do not generate an immune response in syngeneic mice and will form tumors (i.e., "turn*" cells). When these turn* cells are mutagenized, they are rejected by syngeneic mice, and fail to form tumors (thus "turn " "). See Boon et al., Proc. Natl. Acad. Sci. USA 74: 272 (1977), the disclosure of which is incorporated by reference. Many tumor types have been shown to exhibit this phenomenon. See, e.g.. Frost et al.. Cancer Res. 43: 125 (1983). It appears that tum" variants fail to form progressive tumors because they elicit an immune rejection process. The evidence in favor of this hypothesis includes the ability of "turn " " variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel et al., Proc. Natl, Acad. Sci. USA 76: 5282-5285 (1979); and the observation that intraperitoneally injected tum " cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove et al., J. Exp. Med. 152: 1175- 1183 (1980)). Further evidence includes the observation that mice acguire an immune memory which permits them to resist subsequent challenge to the same tum " variant, even when immunosuppressive amounts of radiation are administered with the following challenge of cells (Boon et al., Proc. Natl, Acad. Sci. USA 74: 272-275 (1977); Van Pel et al., supra; Uyttenhove et al. , supra.. Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel et al., J. Exp. Med. 157: 1992-2001 (1983). Thus, it has been shown that it is possible to elicit presentation of a so-called "tumor rejection antigen" in a tumor which is a target for a syngeneic rejection response. Similar results have been obtained when foreign genes have been transfected into spontaneous tumors. See Fearson et al., Cancer Res. 48: 2975- 1980 (1988) in this regard. A class of antigens has been recognized which are presented on the surface of tumor cells and are recognized by cytotoxic T cells, leading to lysis. This class of antigens will be referred to as "tumor rejection antigens" or "TRAs" hereafter. TRAs may or may not elicit antibody responses. The extent to which these antigens have been studied, has been via cytolytic T cell characterization studies in vitro i.e., the study of the identification of the antigen by a particular cytolytic T cell ("CTL" hereafter) subset. The subset proliferates upon recognition of the presented tumor rejection antigen, and the cells presenting the antigen are lysed. Characterization studies have identified CTL clones which specifically lyse cells expressing the antigens. Examples of this work may be found in Levy et al., Adv. Cancer Res. 24: 1- 59 (1977); Boon et al., J. Exp. Med. 152: 1184-1193 (1980); Brunner et al., J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982); Palladino et al., Cane. Res. 47: 5074-5079 (1987). This type of analysis is required for other types of antigens recognized by CTLs, including major histocompatibility antigens, the male specific H-Y antigens, and a class of antigens, referred to as "turn-" antigens, and discussed herein. A tumor exemplary of the subject matter described supra is known as P815. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988); Szikora et al. , EMBO J 9: 1041-1050 (1990), and Sibille et al., J. Exp. Med. 172: 35-45 (1990), the disclosures of which are incorporated by reference. The P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line. The P815 line has generated many tum " variants following mutagenesis, including variants referred to as P91A (DePlaen, supra.. 35B (Szikora, supra.. and P198 (Sibille, supra.. In contrast to tumor rejection antigens - and this is a key distinction - the tum " antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis. Hence, with reference to the literature, a cell line can be turn*, such as the line referred to as "PI", and can be provoked to produce tum ' variants. Since the tum " phenotype differs from that of the parent cell line, one expects a difference in the DNA of tum" cell lines as compared to their turn* parental lines, and this difference can be exploited to locate the gene of interest in turn" cells. As a result, it was found that genes of tum " variants such as P91A, 35B and P198 differ from their normal alleles by point mutations in the coding regions of the gene. See Szikora and Sibille, supra. and Lurquin et al.. Cell 58: 293-303 (1989). This has proved not to be the case with the TRAs of this invention. These papers also demonstrated that peptides derived from the tum " antigen are presented by the L d molecule for recognition by CTLs. P91A is presented by L d , P35 by D d and PI98 by K a . Prior patent applications PCT/US92/04354, U.S. Serial No. 807,043; 764,364; 728,838 and 705,702, all of which are incorporated by reference and U.S. Patent No. 5,342,774, describe inventions involving, inter alia, genes and other nucleic acid molecules which code for various TRAPs, which are in turn processed to tumor rejection antigen, or "TRAs". SEQ ID NOS: 1-26 which are a part of the subject application present seguences of genes coding for various TRAPs, and the TRA referred to hereafter as MZ2E, which is derived from MAGE-1 TRAP (SEQ ID NO: 26). The genes are useful as a source for the isolated and purified tumor rejection antigen precursor and the TRA themselves, either of which can be used as an agent for treating the cancer for which the antigen is a "marker", as well as in various diagnostic and surveillance approaches to oncology, discussed infra. It is known, for example, that tum " cells can be used to generate CTLs which lyse cells presenting different tum" antigens as well as tum + cells. See, e.g., Maryanski et al., Eur. J. Immunol 12: 401 (1982); and Van den Eynde et al., Modern Trends in Leukemia IX (June 1990) , the disclosures of which are incorporated by reference. The tumor rejection antigen precursor may be expressed in cells transfected by the gene, and then used to generate an immune response against a tumor of interest. In the parallel case of human neoplasms, it has been observed that autologous mixed lymphocyte-tumor cell cultures ("MLTC" hereafter) frequently generate responder lymphocytes which lyse autologous tumor cells and do not lyse natural killer targets, autologous EBV-transformed B cells, or autologous fibroblasts (see Anichini et al., Immunol. Today 8: 385-389 (1987)). This response has been particularly well studied for melanomas, and MLTC have been carried out either with peripheral blood cells or with tumor infiltrating lymphocytes. Examples of the literature in this area including Knuth et al., Proc. Natl. Acad. Sci. USA 86: 2804- 2802 (1984); Mukherji et al., J. Exp. Med. 158: 240 (1983); Herin et all. Int. J. Cane. 39: 390-396 (1987); Topalian et al, J. Clin. Oncol 6: 839-853 (1988). Stable cytolytic T cell clones have been derived from MLTC responder cells, and these clones are specific for the tumor cells. See Mukherji et al., supra. Herin et all, supra , Knuth et al., supra. The antigens recognized on tumor cells by these autologous CTLs do not appear to represent a cultural artifact, since they are found on tumor cells __, vivo. Topalian et al. , supra; Degiovanni et al., Eur. J. Immunol. 20: 1865-1868 (1990). These observations, coupled with the techniques used herein to isolate the genes for specific murine tumor rejection antigen precursors, have led to the isolation of nucleic acid sequences coding for tumor rejection antigen precursors of TRAs presented on human tumors. It is now possible to isolate the nucleic acid sequences which code for tumor rejection antigen precursors, including, but not being limited to those most characteristic of a particular tumor, with ramifications that are described infra. Additional work has focused upon the presentation of TRAs by the class of molecules known as major histocompatibility complexes, or "MHCs". Human forms of these molecules are "human leukocyte antigens" or "HLAs". This work has resulted in several unexpected discoveries regarding the field. Specifically in U.S. patent application Serial Number 938,334, now U.S. Patent No. the disclosure of which is incorporated by reference, nonapeptides are taught which are presented by the HLA-Al molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect particular peptides to bind one HLA molecule. These peptides, presented herein as SEQ ID NOS: 27-34 are also presented in Traversari et al., J. Exp. Med. 176: 1453-1457 (1992). This is important, because different individuals possess different HLA phenotypes. As a result, while identification of particular peptides or of particular motifs, and the peptides which are members thereof, as being partners for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue. In U.S. Patent Application Serial Number 008,446, filed January 22, 1993 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-Cw* 1601 molecules. The disclosure shows that a given TRAP can yield a plurality of TRAs. In U.S. Patent Application Serial Number 994,928, filed December 22, 1992, and incorporated by reference herein, tyrosinase is described as a tumor rejection antigen precursor. This is a well known molecule as per Kwon, U.S. Patent No. 4,898,814. This reference discloses that a molecule which is produced by some normal cells (e.g., melanocytes) , is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules. The peptide presented thereby is described in U.S. Application Serial No. 54,714, filed April 28, 1993. SEQ ID NO: 35 sets forth this peptide. Additional tyrosinase derived peptides presented by HLA molecules are set forth in Serial Nos. 203,054, and 233,305 filed February 28, 1994 and April 26, 1994 and incorporated by reference (SEQ ID NOS: 36-41). Other peptides which are TRAs are described in additional patent applications. U.S. Patent Application Serial No. 195,186, filed February 14, 1994, and incorporated by reference herein, sets forth three peptides (SEQ ID NOS: 42-44 herein), which are derived from MAGE-1 and which complex with HLA-Cw * 1601. Serial No. 196,630, filed February 15, 1994, discloses an unrelated tumor rejection antigen precursor, the so-called "BAGE" gene, and peptides derived therefrom, which are processed and then presented by HLA-Cw * 1601. These are set forth as SEQ ID NOS: 45-48, and this application is incorporated by reference. SEQ ID NO: 48 is the tumor rejection antigen. Additional coding sequences for a tumor rejection antigen precursor are set forth in Serial No. 32,978, filed March 18, 1993 and incorporated by reference. These are included herein as SEQ ID NOS: 49 and 50. A more extended seguence for this gene is set forth in Serial No. 272,351, filed July 8, 1994 incorporated by reference, and is SEQ ID NO: 51. In Serial No. 96,039, filed July 22, 1993, the sequence of tumor rejection antigen precursor GAGE is set forth. See SEQ ID NO: 52 for this information. A series of peptides which provoke lysis by cytolytic T cells when presented by MHC molecules are set forth in Serial No. 217,186, Serial No. 08/217,188, and Serial No. 217,187, all filed on March 24, 1994, and all of which are incorporated by reference herein. The first of these applications discloses MAGE-3 derived peptides presented by HLA-A2. Five peptides are of interest. These are repeated here as SEQ ID NOS: 53-57. The second application presents 11 seguences derived from MAGE-2, believed to complex with HLA-A2.1 molecules (SEQ ID NOS: 58-68). The last of these applications discloses two additional peptides (SEQ ID NOS: 69 and 70) derived from MAGE-3 which complex to HLA-A2. Serial No. 190,411, filed April 1, 1994 and incorporated by reference, sets forth three peptides (SEQ ID NO: 71-73), derived from MAGE-1, which are immunogenic in that they provoke production of antibodies in a host animal to which they have been administered. Seial No. 253,503, filed June 3, 1994 and incorporated by reference, teaches a further tumor rejection antigen precursor gene (SEQ ID NO:74), and a peptide, derived therefrom (SEQ ID NO:75), whch is presented by HLA-B44 molecules. Further in the application of Coulie, Ikeda and Boon-Falleur, filed concurrently, a sequence coding for a tumor rejection antigen precursor known as DAGE (SEQ ID NO:76) is set forth. DAGE is found almost universally on tumor cells, and only on testis cells with respect to normal cell expression. This makes it especially useful for cancer diagnosis and in the applications disclosed herein. The above listing should not be presumed to be exhaustive of the TRAP and TRA literature, but is presented to show its diversity and the fact that these materials not only provoke T cell proliferation, but also stimulate production of antibodies. It is well known that antibody producing cells can be used as a source to produce hybridomas, which in turn produce monoclonal antibodies. Thus, when the term "antibodies" is used herein, it encompasses both polyclonal and monoclonal antibodies. The parent applications to the present case, including Serial No. 142,368 and Serial No. 190,411, both discuss the usefulness of combining TRAPs or TRAs with various materials as adjuvants, to produce vaccines, immunogenic compositions, etc. Adjuvants, broadly defined, are substances which promote immune responses. Frequently, the adjuvant of choice if Freund's complete adjuvant, or killed fi. pertussis organisms, used in combination with alum precipitated antigen. A general discussion of adjuvants is provided in Goding, Monoclonal Antibodies: Principles & Practice (Second edition, 1986) , at pages 61-63, which are incorporated by reference herein. Godinσ notes, however, that when the antigen of interest is of low molecular weight, or is poorly immunogenic, coupling to an immunogenic carrier is recommended. Such molecules, according to Godinα. generally have molecular weights below about 1000. Among the carriers suggested by Goding, at page 283, are keyhole limpet hemocyanin, bovine serum albumin, ovalbumin, and fowl immunoglobulin. What is problematic about such carriers, however, is that frequently they are also immunogenic themselves. Thus, the immune response may be a general one, with part, most, or all of it being directed against the carrier molecule rather than the immunogen itself. Exemplary of developments in the art as they relate to adjuvants is U.S. Patent No. 5,057,540 to Kensil, et al, the disclosure of which is incorporated by reference herein. Kensil et al disclose the preparation of various saponin extracts, which are useful as adjuvants in immunogenic compositions. As natural products, the extracts are not completely defined. Kensil, et al do provide a complete and enabling disclosure for how various extracts, including QA-7, QA-19, and QA-21 (also referred to as QS-21) are prepared. Experiments are set forth in which bovine serum albumin ("BSA") was combined with various extracts (examples 8 and 9), and where feline leukemia virus recombinant glycoprotein "gp70RΔ was tested, following absorption to aluminum hydroxide (alum). The two immunogens tested, however, are expected to be immunogenic in their own right (gp70RΔ has a molecular weight of 70 kd, and serum albumin has about the same molecular weight) . No experiments were carried out at all on molecules which should, per se, be considered to be poorly or even non-immunogenic, and thus would be expected to require the use of alum absorption or the use of haptenic carriers for provocation of a response. In PCT Application W09219758, which corresponds to defensive publication 7697275, which is incorporated by reference herein, an adjuvant referred to as "MTP-MF59" is disclosed. This adjuvant is used in connection with a Plasmodiu falciparum protein, "Pfs-25-B". This combination is described as a transmission blocking vaccine. The E. falciparum protein is itself large enough to be immunogenic. Thus, none of the art shows that the improved adjuvants can be used in combination with presumptively non-immunogenic proteins and peptides to yield immunologically effective compositions. This is especially true for TRAP and TRA molecules, as outlined supra. It has now been found, surprisingly, that compositions comprising tumor rejection antigen precursors or tumor rejection antigens can be made which, when administered to a subject animal, provoke an immunogenic response. In especially preferred embodiments the immunogenic portion of the composition consists of TRAP or, more preferably TRA molecules, of one or more types, and an adjuvant. Especially preferred are compositions where the adjuvant is QS21, as is disclosed in the Kensil, et al patent, incorporated by reference supra. The immunogens of this invention consist of TRAPs or TRAs, meaning that they do not include haptens, carriers, precipitated alum, or any of the materials normally associated with materials which are or are expected to be poorly immunogenic. In especially preferred embodiments, the compositions consist essentially of the immunogen and the adjuvant. The invention is described in greater detail in the disclosure which follows. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Example The following example demonstrates the use of peptide MZ2E (SEQ ID NO: 26) in connection with adjuvant QS-21. It is to be understood, however, that one may routinely substitute proteins or peptides (the first component of the composition) and adjuvants (the second component of the composition). The unexpected effect of the combination of MZ2E and QS21 should occur in the alternate combinations, i.e., when other peptides are used. Subjects tested are patients with stage IV melanoma or high risk stage III malignant melanoma. Stage IV patients have a median survival time of one year following diagnosis, and only a 15% chance of long-term survival (Balch, et al, Cutaneous Melanoma. J.b. Lippincott, Philadelphia, 1992). The standard therapy for these patients includes treatment with decarbazine or drug combinations with decarbazine; however, response rates only range from 8-25%, and there is no evidence of the treatment extending survival. Balch et al. supra. Patients with high risk Stage III melanoma (pT4 thick truncal primary tumors or extremity melanomas, with five or more positive regional lymph nodes) have a median survival of 1-2 years following onset, and a 19% chance of long term survival. Balch, et al, supra♦ Twelve patients are used in the study, all of whom have either Stage IV or high risk Stage III malignant melanoma in accordance with the criteria provided supra. confirmed by review of histology. The patients fulfil the following additional criteria: (i) complete recovery from surgery; (ii) no chemotherapy or immunotherapy, within the four weeks preceding immunization; (iii) expected survival of at least three months; (iv) Karnofsky Performance Status of 60 or more; (v) Laboratory results as follows: granulocytes > 2,500/min 3 lymphocytes > 700/min 3 platelets > 100,000/min 3 serum creatinine < 2.0 mg/100 ml serum bilirubin < 2.0 mg/100 ml (vi) for MZ2E immunization, patients are positive for HLA-Al; (vii) for MZ2E immunization, the patients'" tumors express MAGE-l; (viii) they be over 19 years old and be capable of giving informed consent in writing. Any potential subjects who satisfy any of the following criteria are excluded: (i) clinically significant heart disease; (ii) other serious illness, such as active infection requiring antibiotics, or bleeding disorders; (iii) treatment with antihistamines, N-SAIDS, or corti- costeroids; (iv) immunodeficiency, splenectomy, or radiation therapy to the spleen; (v) pregnancy or lactation; (vi) women of childbearing age who do not use effective methods of contraception. All subjects are treated as outpatients. They are immunized, subcutaneously, with MZ2E (30 ug or 300 ug) and QS21 (100 ug) , in 0.3 ml phosphate buffered saline, pH 7.4. Six patients receive 30 ug of peptide, and six receive 300 ug. The first injection is into the deltoid region of the anterior aspect of the thigh, and the site of injection is changed with follow up injections. No injections are given into limbs where draining lymph nodes have been surgically removed or irradiated. Injections are given at day 1, and then at days 8, 15, 22, and 57. Patients are monitored over a course of 12 weeks, unless intervention is required (as determined by the investigator). Any patients who show stabilization or tumor response remain in the study until disease progression is evidenced. Patients may also be removed from the study or receive different doses of the peptide, if toxicity reactions are observed. The patients show response as follows. In a complete response, all signs, symptoms, biochemical and imaging evidence of tumor disappear for a period of at least 30 days. In a partial response, there is a decrease in size of all measurable tumors of at least 50% of the sum of products of the greatest and perpendicular diameters for at least 30 days, without the appearance of new lesions or progression of any new lesions. In a minor response, there is a decrease in size of all measurable tumors of at least 25% of the sum of products of greatest and perpendicular diameters, for at least 30 days, without appearance of new lesions or progression of any lesion. In stable disease, there is a change of less than 25% of the sum of products of greatest and perpendicular diameters, for at least 30 days, without the appearance of new lesions or progression of lesions. In progression of the disease, there is appearance of new tumors, or an increase in the size of measurable tumors of at least 50% of the sum of the product of greatest and perpendicular diameter. The foregoing example demonstrates a composition comprising an amount of a tumor rejection antigen, i.e., MZ2E, and an adjuvant, i.e., QS21, and the use of the composition in the in vivo treatment of cancer (i.e., melanoma). The tumor rejection antigen is used in an amount sufficient to provoke an immune response against tumor cells which present it on their surface. The compositions of the invention comprise any tumor rejection antigen precursor ("TRAP") or tumor rejection antigen ("TRA"), in combination with a pharmaceutically acceptable adjuvant. Preferred embodiments of the invention utilize the TRAPs and TRAs discussed supra and set forth in SEQ ID NO: 65, as well as the adjuvants described in the Background section. As will be seen from the foregoing discussion, an important aspect of the invention is stimulation of proliferation of T cells. This can be an initial stimulation or an augmentation of a prior stimulation. In particular, it is desirable to stimulate cytolytic T cells which present peptides, such as the TRAs described herein, on their surfaces. The cytolytic T cells recognize these complexes of MHC and peptide, bind thereto via their receptor, and proliferate. They also lyse the recognized cells. This response can be used not only in vivo, but in vitro. as it is well established that cytolytic T cells specific for particular complexes of MHC and peptide are present in the blood of subjects who have experienced cell transformation. By contacting a blood sample of individuals in vitro with the peptide of interest and cells which present the MHC molecule of interest, any cytolytic T cells in the blood sample will expand, i.e., proliferate. This proliferation an be measured via any of the well known assays designed therefor. Especially preferred are the radioactive chromium ( 51 Cr) release assay, and the measurement of release of tumor necrosis factor (TNF) . The compositions are also useful as stimulators of B cell proliferation, or antibody production. Again, it is well known that B cells produce antibodies, and the size of their targets are well within the sizes of the tumor rejection antigens, and certainly the tumor rejection antigen precursors. As with T cells, the stimulation may be "ab initio", or an augmentation of a prior response, in vitro or in vivo. The amount of TRAP or TRA used will vary, depending upon the purpose of the immunization and the subject to which it is administered. For example, in the case of generating murine antibodies which can then be used, e.g. , to diagnose for the presence of cancer cells presenting a TRA, the amount of protein or peptide may be less than that used in a course of in vivo therapy, such as that described in the example, supra. In general, a preferred dose can range from about l ug to about 750 ug of protein or peptide per dose. In a preferred embodiment, the range is from about 10 ug to about 500 ug. Most preferably, anywhere from about 30 ug to about 300 ug per dose may be used. Of course, in the context of the therapeutic aspect of the invention, the investigator will modify the dose, as a six month old infant will require dosing different from a full grown man, e.g. The mode of administration may vary, with preferred forms being oral, subcutaneous, intramuscular, intravenous and intraperitoneal adminstration. The choice of TRAP or TRA protein or peptide in the composition will depend upon parameters determinable by the artisan. It is art recognized, for example, that different TRAs are presented by the various MHC molecules. As such, if a subject is typed, using well known techniques, as presenting HLA-A2 molecules on the surface of tumor cells, one will use a TRA presented by HLA-A2 molecules rather than one presented by, e.g., HLA-Cw * 1601. Similarly, using techniques such as polymerase chain reaction ("PCR"), lysis studies, and other assay methodologies which are well known in the art, one can determine which tumor rejection antigen precursor gene or genes are being expressed by a subject patient. This will lead to the decision as to what protein or peptide to use. Again, by way of example, if a subject's tumor cells are expressing MAGE-3 but not MAGE-1, the peptide used in immunization should be derived from MAGE-3, and not MAGE-1. While the molecules discussed herein are referred to as "tumor" rejection antigens and "tumor" rejection antigen precursors, it is intended that their use, in a therapeutic and also a diagnostic context, extends beyond cancer per se. The art is familiar with pathological conditions, such as displastic nevis, which are not cancer per se, but where the cells of the afflicted individuals are in fact characterized by transformation. Any and all such conditions are within the intended ambit of the invention. Other aspects of the invention will be clear to the skilled artisan and need not be reiterated here. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention. (1) GENERAL INFORMATION: (i) APPLICANTS: Boon-Falleur, Thierry; van den Eynde, Benoit; van der Bruggen, Pierre (ii) TITLE OF INVENTION: COMPOSITIONSCONTAININGTUMORREJECTION ANTIGEN PRECURSORS OR TUMOR REJECTION ANTIGENS, AND AN ADJUVANT AND/OR GROWTH FACTOR (iii) NUMBER OF SEQUENCES: 76 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Felfe & Lynch (B) STREET: 805 Third Avenue (C) CITY: New York City (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10022 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage (B) COMPUTER: IBM PS/2 (C) OPERATING SYSTEM: PC-DOS (D) SOFTWARE: Wordperfect (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 08/315,961 (B) FILING DATE: 30-SEPTEMBER-1994 (C) CLASSIFICATION: 435 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US92/04354 (B) FILING DATE: 22-MAY-1992 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/938,334 (B) FILING DATE: 31-AUGUST-1992 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/008,446 (B) FILING DATE: 22-JANUARY-1993 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/054,714 (B) FILING DATE: 28-APRIL-1993 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/203,054 (B) FILING DATE: 28-FEBRUARY-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/233,305 (B) FILING DATE: 26-APRIL-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/195,186 (B) FILING DATE: 14-FEBRUARY-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/196,630 (B) FILING DATE: 15-FEBRUARY-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/032,978 (B) FILING DATE: 18-MARCH-1993 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/217,186 (B) FILING DATE: 24-MARCH-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/217,187 (B) FILING DATE: 24-MARCH-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/217,188 (B) FILING DATE: 24-MARCH-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/190,411 (B) FILING DATE: l-APRIL-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/253,503 (B) FILING DATE: 3-JUNE-1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Hanson, Norman D. (B) REGISTRATION NUMBER: 30,946 (C) REFERENCE/DOCKET NUMBER: LUD 5370 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 688-9200 (B) TELEFAX: (212) 838-3884 (2) INFORMATION FOR SEQUENCE ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 462 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT GAAGATCCTG 60 ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT CAGCCAATGA GCTTACTGTT 120 CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG 180 CTTGTGAATT TGTACCCTTT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC 240 CCCCCTCCCA CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG CATGCATTGT 360 GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG CTAGCTTGCG ACTCTACTCT 420 TATCTTAACT TAGCTCGGCT TCCTGCTGGT ACCCTTTGTG CC 462 (2) INFORMATION FOR SEQUENCE ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 675 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT 48 Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly 5 10 15 GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA 96 Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Glu 20 25 30 GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC TTC GCT GTT GTC ACA ACA 144 Glu He Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Val Val Thr Thr 35 40 45 AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC CTT TAT GAG GAG CAG 192 Ser Phe Leu Ala Leu Gin Met Phe He Asp Ala Leu Tyr Glu Glu Gin 50 55 60 TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC 240 Tyr Glu Arg Asp Val Ala Trp He Ala Arg Gin Ser Lys Arg Met Ser 65 70 75 80 TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC 288 Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr 85 90 95 GAC GAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 336 Asp Asp Glu Asp Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp 100 105 110 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA GAT GAG 384 Glu Glu Glu Glu Leu Glu Asn Leu Met Asp Asp Glu Ser Glu Asp Glu 115 120 125 GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA GCT GAG GAA ATG 432 Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly Ala Glu Glu Met 130 135 140 GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT GGC CAT CAT TTA AGG AAG 480 Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys 145 150 155 160 AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC 528 Asn Glu Val Lys Cys Arg Met He Tyr Phe Phe His Asp Pro Asn Phe 165 170 175 CTG GTG TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT 576 Leu Val Ser He Pro Val Asn Pro Lys Glu Gin Met Glu Cys Arg Cys 180 185 190 GAA AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG 624 Glu Asn Ala Asp Glu Glu Val Ala Met Glu Glu Glu Glu Glu Glu Glu 195 200 210 GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 672 Glu Glu Glu Glu Glu Glu Glu Met Gly Asn Pro Asp Gly Phe Ser Pro 220 225 230 235 TAG 675 (2) INFORMATION FOR SEQUENCE ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG TTGTTTTTTT 60 TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA ATTTGATTTT GTTCTAAAGT 120 TCATTATGCA AAGATGTCAC CAACAGACTT CTGACTGCAT GGTGAACTTT CATATGATAC 180 ATAGGATTAC ACTTGTACCT GTTAAAAATA AAAGTTTGAC TTGCATAC 228 (2) INFORMATION FOR SEQUENCE ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1365 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50 GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100 CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150 AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200 CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250 CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG 350 CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400 CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450 ACCCTTTGTG CC 462 ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504 GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546 TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588 TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630 ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672 TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714 GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756 GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840 GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882 GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT 924 GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT AGG ATG ATT 966 TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT ATA CCA GTG 1008 AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA AAT GCT GAT 1050 GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG GAG GAG 1092 GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 1134 TAG 1137 GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG 1187 TTGTTTTTTT TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA 1237 ATTTGATTTT GTTCTAAAGT TCATTATGCA AAGATGTCAC CAACAGACTT 1287 CTGACTGCAT GGTGAACTTT CATATGATAC ATAGGATTAC ACTTGTACCT 1337 GTTAAAAATA AAAGTTTGAC TTGCATAC 1365 (2) INFORMATION FOR SEQUENCE ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4698 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50 GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100 CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150 AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200 CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250 CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG 350 CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400 CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450 ACCCTTTGTG CC 462 ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504 GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546 TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588 TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630 ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672 TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714 GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756 GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840 GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882 GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC T 916 GTGAGTAACC CGTGGTCTTT ACTCTAGATT CAGGTGGGGT GCATTCTTTA 966 CTCTTGCCCA CATCTGTAGT AAAGACCACA TTTTGGTTGG GGGTCATTGC 1016 TGGAGCCATT CCTGGCTCTC CTGTCCACGC CTATCCCCGC TCCTCCCATC 1066 CCCCACTCCT TGCTCCGCTC TCTTTCCTTT TCCCACCTTG CCTCTGGAGC 1116 TTCAGTCCAT CCTGCTCTGC TCCCTTTCCC CTTTGCTCTC CTTGCTCCCC 1166 TCCCCCTCGG CTCAACTTTT CGTGCCTTCT GCTCTCTGAT CCCCACCCTC 1216 TTCAGGCTTC CCCATTTGCT CCTCTCCCGA AACCCTCCCC TTCCTGTTCC 1266 CCTTTTCGCG CCTTTTCTTT CCTGCTCCCC TCCCCCTCCC TATTTACCTT 1316 TCACCAGCTT TGCTCTCCCT GCTCCCCTCC CCCTTTTGCA CCTTTTCTTT 1366 TCCTGCTCCC CTCCCCCTCC CCTCCCTGTT TACCCTTCAC CGCTTTTCCT 1416 CTACCTGCTT CCCTCCCCCT TGCTGCTCCC TCCCTATTTG CATTTTCGGG 1466 TGCTCCTCCC TCCCCCTCCC CCTCCCTCCC TATTTGCATT TTCGGGTGCT 1516 CCTCCCTCCC CCTCCCCAGG CCTTTTTTTT TTTTTTTTTT TTTTTTTTTT 1566 TTGGTTTTTC GAGACAGGGT TTCTCTTTGT ATCCCTGGCT GTCCTGGCAC 1616 TCACTCTGTA GACCAGGCTG GCCTCAAACT CAGAAATCTG CCTGCCTCTG 1666 CCTCCCAAAT GCTGGGATTA AAGGCTTGCA CCAGGACTGC CCCAGTGCAG 1716 GCCTTTCTTT TTTCTCCTCT CTGGTCTCCC TAATCCCTTT TCTGCATGTT 1766 AACTCCCCTT TTGGCACCTT TCCTTTACAG GACCCCCTCC CCCTCCCTGT 1816 TTCCCTTCCG GCACCCTTCC TAGCCCTGCT CTGTTCCCTC TCCCTGCTCC 1866 CCTCCCCCTC TTTGCTCGAC TTTTAGCAGC CTTACCTCTC CCTGCTTTCT 1916 GCCCCGTTCC CCTTTTTTGT GCCTTTCCTC CTGGCTCCCC TCCACCTTCC 1966 AGCTCACCTT TTTGTTTGTT TGGTTGTTTG GTTGTTTGGT TTGCTTTTTT 2016 TTTTTTTTTT GCACCTTGTT TTCCAAGATC CCCCTCCCCC TCCGGCTTCC 2066 CCTCTGTGTG CCTTTCCTGT TCCCTCCCCC TCGCTGGCTC CCCCTCCCTT 2116 TCTGCCTTTC CTGTCCCTGC TCCCTTCTCT GCTAACCTTT TAATGCCTTT 2166 CTTTTCTAGA CTCCCCCCTC CAGGCTTGCT GTTTGCTTCT GTGCACTTTT 2216 CCTGACCCTG CTCCCCTTCC CCTCCCAGCT CCCCCCTCTT TTCCCACCTC 2266 CCTTTCTCCA GCCTGTCACC CCTCCTTCTC TCCTCTCTGT TTCTCCCACT 2316 TCCTGCTTCC TTTACCCCTT CCCTCTCCCT ACTCTCCTCC CTGCCTGCTG 2366 GACTTCCTCT CCAGCCGCCC AGTTCCCTGC AGTCCTGGAG TCTTTCCTGC 2416 CTCTCTGTCC ATCACTTCCC CCTAGTTTCA CTTCCCTTTC ACTCTCCCCT 2466 ATGTGTCTCT CTTCCTATCT ATCCCTTCCT TTCTGTCCCC TCTCCTCTGT 2516 CCATCACCTC TCTCCTCCCT TCCCTTTCCT CTCTCTTCCA TTTTCTTCCA 2566 CCTGCTTCTT TACCCTGCCT CTCCCATTGC CCTCTTACCT TTATGCCCAT 2616 TCCATGTCCC CTCTCAATTC CCTGTCCCAT TGTGCTCCCT CACATCTTCC 2666 ATTTCCCTCT TTCTCCCTTA GCCTCTTCTT CCTCTTCTCT TGTATCTCCC 2716 TTCCCTTTGC TTCTCCCTCC TCCTTTCCCC TTCCCCTATG CCCTCTACTC 2766 TACTTGATCT TCTCTCCTCT CCACATACCC TTTTTCCTTT CCACCCTGCC 2816 CTTTGTCCCC AGACCCTACA GTATCCTGTG CACAGGAAGT GGGAGGTGCC 2866 ATCAACAACA AGGAGGCAAG AAACAGAGCA AAATCCCAAA ATCAGCAGGA 2916 AAGGCTGGAT GAAAATAAGG CCAGGTTCTG AGGACAGCTG GAATCTAGCC 2966 AAGTGGCTCC TATAACCCTA AGTACCAAGG GAGAAAGTGA TGGTGAAGTT 3016 CTTGATCCTT GCTGCTTCTT TTACATATGT TGGCACATCT TTCTCAAATG 3066 CAGGCCATGC TCCATGCTTG GCGCTTGCTC AGCGTGGTTA AGTAATGGGA 3116 GAATCTGAAA ACTAGGGGCC AGTGGTTTGT TTTGGGGACA AATTAGCACG 3166 TAGTGATATT TCCCCCTAAA AATTATAACA AACAGATTCA TGATTTGAGA 3216 TCCTTCTACA GGTGAGAAGT GGAAAAATTG TCACTATGAA GTTCTTTTTA 3266 GGCTAAAGAT ACTTGGAACC ATAGAAGCGT TGTTAAAATA CTGCTTTCTT 3316 TTGCTAAAAT ATTCTTTCTC ACATATTCAT ATTCTCCAG 3355 GT GTT CCT GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT 3396 AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT 3438 ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA 3480 AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA 3522 GAG GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC 3564 TTC TCA CCT TAG 3576 GCATGCAGGT ACTGGCTTCA CTAACCAACC ATTCCTAACA TATGCCTGTA 3626 GCTAAGAGCA TCTTTTTAAA AAATATTATT GGTAAACTAA ACAATTGTTA 3676 TCTTTTTACA TTAATAAGTA TTAAATTAAT CCAGTATACA GTTTTAAGAA 3726 CCCTAAGTTA AACAGAAGTC AATGATGTCT AGATGCCTGT TCTTTAGATT 3776 GTAGTGAGAC TACTTACTAC AGATGAGAAG TTGTTAGACT CGGGAGTAGA 3826 GACCAGTAAA AGATCATGCA GTGAAATGTG GCCATGGAAA TCGCATATTG 3876 TTCTTATAGT ACCTTTGAGA CAGCTGATAA CAGCTGACAA AAATAAGTGT 3926 TTCAAGAAAG ATCACACGCC ATGGTTCACA TGCAAATTAT TATTTTGTCG 3976 TTCTGATTTT TTTCATTTCT AGACCTGTGG TTTTAAAGAG ATGAAAATCT 4026 CTTAAAATTT CCTTCATCTT TAATTTTCCT TAACTTTAGT TTTTTTCACT 4076 TAGAATTCAA TTCAAATTCT TAATTCAATC TTAATTTTTA GATTTCTTAA 4126 AATGTTTTTT AAAAAAAATG CAAATCTCAT TTTTAAGAGA TGAAAGCAGA 4176 GTAACTGGGG GGCTTAGGGA ATCTGTAGGG TTGCGGTATA GCAATAGGGA 4226 GTTCTGGTCT CTGAGAAGCA GTCAGAGAGA ATGGAAAACC AGGCCCTTGC 4276 CAGTAGGTTA GTGAGGTTGA TATGATCAGA TTATGGACAC TCTCCAAATC 4326 ATAAATACTC TAACAGCTAA GGATCTCTGA GGGAAACACA ACAGGGAAAT 4376 ATTTTAGTTT CTCCTTGAGA AACAATGACA AGACATAAAA TTGGCAAGAA 4426 AGTCAGGAGT GTATTCTAAT AAGTGTTGCT TATCTCTTAT TTTCTTCTAC 4476 AGTTGCAAAG CCCAGAAGAA AGAAATGGAC AGCGGAAGAA GTGGTTGTTT 4526 TTTTTTCCCC TTCATTAATT TTCTAGTTTT TAGTAATCCA GAAAATTTGA 4576 TTTTGTTCTA AAGTTCATTA TGCAAAGATG TCACCAACAG ACTTCTGACT 4626 GCATGGTGAA CTTTCATATG ATACATAGGA TTACACTTGT ACCTGTTAAA 4676 AATAAAAGTT TGACTTGCAT AC 4698 (2) INFORMATION FOR SEQUENCE ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Leu Pro Tyr Leu Gly Trp Leu Val Phe 5 (2) INFORMATION FOR SEQUENCE ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2419 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: GGATCCAGGC CCTGCCAGGA AAAATATAAG GGCCCTGCGT GAGAACAGAG 50 GGGGTCATCC ACTGCATGAG AGTGGGGATG TCACAGAGTC CAGCCCACCC 100 TCCTGGTAGC ACTGAGAAGC CAGGGCTGTG CTTGCGGTCT GCACCCTGAG 150 GGCCCGTGGA TTCCTCTTCC TGGAGCTCCA GGAACCAGGC AGTGAGGCCT 200 TGGTCTGAGA CAGTATCCTC AGGTCACAGA GCAGAGGATG CACAGGGTGT 250 GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300 CAGGACACAT AGGACTCCAC AGAGTCTGGC CTCACCTCCC TACTGTCAGT 350 CCTGTAGAAT CGACCTCTGC TGGCCGGCTG TACCCTGAGT ACCCTCTCAC 400 TTCCTCCTTC AGGTTTTCAG GGGACAGGCC AACCCAGAGG ACAGGATTCC 450 CTGGAGGCCA CAGAGGAGCA CCAAGGAGAA GATCTGTAAG TAGGCCTTTG 500 TTAGAGTCTC CAAGGTTCAG TTCTCAGCTG AGGCCTCTCA CACACTCCCT 550 CTCTCCCCAG GCCTGTGGGT CTTCATTGCC CAGCTCCTGC CCACACTCCT 600 GCCTGCTGCC CTGACGAGAG TCATCATGTC TCTTGAGCAG AGGAGTCTGC 650 ACTGCAAGCC TGAGGAAGCC CTTGAGGCCC AACAAGAGGC CCTGGGCCTG 700 GTGTGTGTGC AGGCTGCCAC CTCCTCCTCC TCTCCTCTGG TCCTGGGCAC 750 CCTGGAGGAG GTGCCCACTG CTGGGTCAAC AGATCCTCCC CAGAGTCCTC 800 AGGGAGCCTC CGCCTTTCCC ACTACCATCA ACTTCACTCG ACAGAGGCAA 850 CCCAGTGAGG GTTCCAGCAG CCGTGAAGAG GAGGGGCCAA GCACCTCTTG 900 TATCCTGGAG TCCTTGTTCC GAGCAGTAAT CACTAAGAAG GTGGCTGATT 950 TGGTTGGTTT TCTGCTCCTC AAATATCGAG CCAGGGAGCC AGTCACAAAG 1000 GCAGAAATGC TGGAGAGTGT CATCAAAAAT TACAAGCACT GTTTTCCTGA 1050 GATCTTCGGC AAAGCCTCTG AGTCCTTGCA GCTGGTCTTT GGCATTGACG 1100 TGAAGGAAGC AGACCCCACC GGCCACTCCT ATGTCCTTGT CACCTGCCTA 1150 GGTCTCTCCT ATGATGGCCT GCTGGGTGAT AATCAGATCA TGCCCAAGAC 1200 AGGCTTCCTG ATAATTGTCC TGGTCATGAT TGCAATGGAG GGCGGCCATG 1250 CTCCTGAGGA GGAAATCTGG GAGGAGCTGA GTGTGATGGA GGTGTATGAT 1300 GGGAGGGAGC ACAGTGCCTA TGGGGAGCCC AGGAAGCTGC TCACCCAAGA 1350 TTTGGTGCAG GAAAAGTACC TGGAGTACGG CAGGTGCCGG ACAGTGATCC 1400 CGCACGCTAT GAGTTCCTGT GGGGTCCAAG GGCCCTCGCT GAAACCAGCT 1450 ATGTGAAAGT CCTTGAGTAT GTGATCAAGG TCAGTGCAAG AGTTCGCTTT 1500 TTCTTCCCAT CCCTGCGTGA AGCAGCTTTG AGAGAGGAGG AAGAGGGAGT 1550 CTGAGCATGA GTTGCAGCCA AGGCCAGTGG GAGGGGGACT GGGCCAGTGC 1600 ACCTTCCAGG GCCGCGTCCA GCAGCTTCCC CTGCCTCGTG TGACATGAGG 1650 CCCATTCTTC ACTCTGAAGA GAGCGGTCAG TGTTCTCAGT AGTAGGTTTC 1700 TGTTCTATTG GGTGACTTGG AGATTTATCT TTGTTCTCTT TTGGAATTGT 1750 TCAAATGTTT TTTTTTAAGG GATGGTTGAA TGAACTTCAG CATCCAAGTT 1800 TATGAATGAC AGCAGTCACA CAGTTCTGTG TATATAGTTT AAGGGTAAGA 1850 GTCTTGTGTT TTATTCAGAT TGGGAAATCC ATTCTATTTT GTGAATTGGG 1900 ATAATAACAG CAGTGGAATA AGTACTTAGA AATGTGAAAA ATGAGCAGTA 1950 AAATAGATGA GATAAAGAAC TAAAGAAATT AAGAGATAGT CAATTCTTGC 2000 CTTATACCTC AGTCTATTCT GTAAAATTTT TAAAGATATA TGCATACCTG 2050 GATTTCCTTG GCTTCTTTGA GAATGTAAGA GAAATTAAAT CTGAATAAAG 2100 AATTCTTCCT GTTCACTGGC TCTTTTCTTC TCCATGCACT GAGCATCTGC 2150 TTTTTGGAAG GCCCTGGGTT AGTAGTGGAG ATGCTAAGGT AAGCCAGACT 2200 CATACCCACC CATAGGGTCG TAGAGTCTAG GAGCTGCAGT CACGTAATCG 2250 AGGTGGCAAG ATGTCCTCTA AAGATGTAGG GAAAAGTGAG AGAGGGGTGA 2300 GGGTGTGGGG CTCCGGGTGA GAGTGGTGGA GTGTCAATGC CCTGAGCTGG 2350 GGCATTTTGG GCTTTGGGAA ACTGCAGTTC CTTCTGGGGG AGCTGATTGT 2400 AATGATCTTG GGTGGATCC 2419 (2) INFORMATION FOR SEQUENCE ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5674 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-1 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: CCCGGGGCAC CACTGGCATC CCTCCCCCTA CCACCCCCAA TCCCTCCCTT 50 TACGCCACCC ATCCAAACAT CTTCACGCTC ACCCCCAGCC CAAGCCAGGC 100 AGAATCCGGT TCCACCCCTG CTCTCAACCC AGGGAAGCCC AGGTGCCCAG 150 ATGTGACGCC ACTGACTTGA GCATTAGTGG TTAGAGAGAA GCGAGGTTTT 200 CGGTCTGAGG GGCGGCTTGA GATCGGTGGA GGGAAGCGGG CCCAGCTCTG 250 TAAGGAGGCA AGGTGACATG CTGAGGGAGG ACTGAGGACC CACTTACCCC 300 AGATAGAGGA CCCCAAATAA TCCCTTCATG CCAGTCCTGG ACCATCTGGT 350 GGTGGACTTC TCAGGCTGGG CCACCCCCAG CCCCCTTGCT GCTTAAACCA 400 CTGGGGACTC GAAGTCAGAG CTCCGTGTGA TCAGGGAAGG GCTGCTTAGG 450 AGAGGGCAGC GTCCAGGCTC TGCCAGACAT CATGCTCAGG ATTCTCAAGG 500 AGGGCTGAGG GTCCCTAAGA CCCCACTCCC GTGACCCAAC CCCCACTCCA 550 ATGCTCACTC CCGTGACCCA ACCCCCTCTT CATTGTCATT CCAACCCCCA 600 CCCCACATCC CCCACCCCAT CCCTCAACCC TGATGCCCAT CCGCCCAGCC 650 ATTCCACCCT CACCCCCACC CCCACCCCCA CGCCCACTCC CACCCCCACC 700 CAGGCAGGAT CCGGTTCCCG CCAGGAAACA TCCGGGTGCC CGGATGTGAC 750 GCCACTGACT TGCGCATTGT GGGGCAGAGA GAAGCGAGGT TTCCATTCTG 800 AGGGACGGCG TAGAGTTCGG CCGAAGGAAC CTGACCCAGG CTCTGTGAGG 850 AGGCAAGGTG AGAGGCTGAG GGAGGACTGA GGACCCCGCC ACTCCAAATA 900 GAGAGCCCCA AATATTCCAG CCCCGCCCTT GCTGCCAGCC CTGGCCCACC 950 CGCGGGAAGA CGTCTCAGCC TGGGCTGCCC CCAGACCCCT GCTCCAAAAG 1000 CCTTGAGAGA CACCAGGTTC TTCTCCCCAA GCTCTGGAAT CAGAGGTTGC 1050 TGTGACCAGG GCAGGACTGG TTAGGAGAGG GCAGGGCACA GGCTCTGCCA 1100 GGCATCAAGA TCAGCACCCA AGAGGGAGGG CTGTGGGCCC CCAAGACTGC 1150 ACTCCAATCC CCACTCCCAC CCCATTCGCA TTCCCATTCC CCACCCAACC 1200 CCCATCTCCT CAGCTACACC TCCACCCCCA TCCCTACTCC TACTCCGTCA 1250 CCTGACCACC ACCCTCCAGC CCCAGCACCA GCCCCAACCC TTCTGCCACC 1300 TCACCCTCAC TGCCCCCAAC CCCACCCTCA TCTCTCTCAT GTGCCCCACT 1350 CCCATCGCCT CCCCCATTCT GGCAGAATCC GGTTTGCCCC TGCTCTCAAC 1400 CCAGGGAAGC CCTGGTAGGC CCGATGTGAA ACCACTGACT TGAACCTCAC 1450 AGATCTGAGA GAAGCCAGGT TCATTTAATG GTTCTGAGGG GCGGCTTGAG 1500 ATCCACTGAG GGGAGTGGTT TTAGGCTCTG TGAGGAGGCA AGGTGAGATG 1550 CTGAGGGAGG ACTGAGGAGG CACACACCCC AGGTAGATGG CCCCAAAATG 1600 ATCCAGTACC ACCCCTGCTG CCAGCCCTGG ACCACCCGGC CAGGACAGAT 1650 GTCTCAGCTG GACCACCCCC CGTCCCGTCC CACTGCCACT TAACCCACAG 1700 GGCAATCTGT AGTCATAGCT TATGTGACCG GGGCAGGGTT GGTCAGGAGA 1750 GGCAGGGCCC AGGCATCAAG GTCCAGCATC CGCCCGGCAT TAGGGTCAGG 1800 ACCCTGGGAG GGAACTGAGG GTTCCCCACC CACACCTGTC TCCTCATCTC 1850 CACCGCCACC CCACTCACAT TCCCATACCT ACCCCCTACC CCCAACCTCA 1900 TCTTGTCAGA ATCCCTGCTG TCAACCCACG GAAGCCACGG GAATGGCGGC 1950 CAGGCACTCG GATCTTGACG TCCCCATCCA GGGTCTGATG GAGGGAAGGG 2000 GCTTGAACAG GGCCTCAGGG GAGCAGAGGG AGGGCCCTAC TGCGAGATGA 2050 GGGAGGCCTC AGAGGACCCA GCACCCTAGG ACACCGCACC CCTGTCTGAG 2100 ACTGAGGCTG CCACTTCTGG CCTCAAGAAT CAGAACGATG GGGACTCAGA 2150 TTGCATGGGG GTGGGACCCA GGCCTGCAAG GCTTACGCGG AGGAAGAGGA 2200 GGGAGGACTC AGGGGACCTT GGAATCCAGA TCAGTGTGGA CCTCGGCCCT 2250 GAGAGGTCCA GGGCACGGTG GCCACATATG GCCCATATTT CCTGCATCTT 2300 TGAGGTGACA GGACAGAGCT GTGGTCTGAG AAGTGGGGCC TCAGGTCAAC 2350 AGAGGGAGGA GTTCCAGGAT CCATATGGCC CAAGATGTGC CCCCTTCATG 2400 AGGACTGGGG ATATCCCCGG CTCAGAAAGA AGGGACTCCA CACAGTCTGG 2450 CTGTCCCCTT TTAGTAGCTC TAGGGGGACC AGATCAGGGA TGGCGGTATG 2500 TTCCATTCTC ACTTGTACCA CAGGCAGGAA GTTGGGGGGC CCTCAGGGAG 2550 ATGGGGTCTT GGGGTAAAGG GGGGATGTCT ACTCATGTCA GGGAATTGGG 2600 GGTTGAGGAA GCACAGGCGC TGGCAGGAAT AAAGATGAGT GAGACAGACA 2650 AGGCTATTGG AATCCACACC CCAGAACCAA AGGGGTCAGC CCTGGACACC 2700 TCACCCAGGA TGTGGCTTCT TTTTCACTCC TGTTTCCAGA TCTGGGGCAG 2750 GTGAGGACCT CATTCTCAGA GGGTGACTCA GGTCAACGTA GGGACCCCCA 2800 TCTGGTCTAA AGACAGAGCG GTCCCAGGAT CTGCCATGCG TTCGGGTGAG 2850 GAACATGAGG GAGGACTGAG GGTACCCCAG GACCAGAACA CTGAGGGAGA 2900 CTGCACAGAA ATCAGCCCTG CCCCTGCTGT CACCCCAGAG AGCATGGGCT 2950 GGGCCGTCTG CCGAGGTCCT TCCGTTATCC TGGGATCATT GATGTCAGGG 3000 ACGGGGAGGC CTTGGTCTGA GAAGGCTGCG CTCAGGTCAG TAGAGGGAGC 3050 GTCCCAGGCC CTGCCAGGAG TCAAGGTGAG GACCAAGCGG GCACCTCACC 3100 CAGGACACAT TAATTCCAAT GAATTTTGAT ATCTCTTGCT GCCCTTCCCC 3150 AAGGACCTAG GCACGTGTGG CCAGATGTTT GTCCCCTCCT GTCCTTCCAT 3200 TCCTTATCAT GGATGTGAAC TCTTGATTTG GATTTCTCAG ACCAGCAAAA 3250 GGGCAGGATC CAGGCCCTGC CAGGAAAAAT ATAAGGGCCC TGCGTGAGAA 3300 CAGAGGGGGT CATCCACTGC ATGAGAGTGG GGATGTCACA GAGTCCAGCC 3350 5 CACCCTCCTG GTAGCACTGA GAAGCCAGGG CTGTGCTTGC GGTCTGCACC 3400 CTGAGGGCCC GTGGATTCCT CTTCCTGGAG CTCCAGGAAC CAGGCAGTGA 3450 GGCCTTGGTC TGAGACAGTA TCCTCAGGTC ACAGAGCAGA GGATGCACAG 3500 GGTGTGCCAG CAGTGAATGT TTGCCCTGAA TGCACACCAA GGGCCCCACC 3550 TGCCACAGGA CACATAGGAC TCCACAGAGT CTGGCCTCAC CTCCCTACTG 3600 0 TCAGTCCTGT AGAATCGACC TCTGCTGGCC GGCTGTACCC TGAGTACCCT 3650 CTCACTTCCT CCTTCAGGTT TTCAGGGGAC AGGCCAACCC AGAGGACAGG 3700 ATTCCCTGGA GGCCACAGAG GAGCACCAAG GAGAAGATCT GTAAGTAGGC 3750 CTTTGTTAGA GTCTCCAAGG TTCAGTTCTC AGCTGAGGCC TCTCACACAC 3800 TCCCTCTCTC CCCAGGCCTG TGGGTCTTCA TTGCCCAGCT CCTGCCCACA 3850 CTCCTGCCTG CTGCCCTGAC GAGAGTCATC 3880 ATG TCT CTT GAG CAG AGG AGT CTG CAC TGC AAG CCT GAG GAA 3922 GCC CTT GAG GCC CAA CAA GAG GCC CTG GGC CTG GTG TGT GTG 3964 CAG GCT GCC ACC TCC TCC TCC TCT CCT CTG GTC CTG GGC ACC 4006 CTG GAG GAG GTG CCC ACT GCT GGG TCA ACA GAT CCT CCC CAG 4048 AGT CCT CAG GGA GCC TCC GCC TTT CCC ACT ACC ATC AAC TTC 4090 ACT CGA CAG AGG CAA CCC AGT GAG GGT TCC AGC AGC CGT GAA 4132 GAG GAG GGG CCA AGC ACC TCT TGT ATC CTG GAG TCC TTG TTC 4174 CGA GCA GTA ATC ACT AAG AAG GTG GCT GAT TTG GTT GGT TTT 4216 CTG CTC CTC AAA TAT CGA GCC AGG GAG CCA GTC ACA AAG GCA 4258 GAA ATG CTG GAG AGT GTC ATC AAA AAT TAC AAG CAC TGT TTT 4300 CCT GAG ATC TTC GGC AAA GCC TCT GAG TCC TTG CAG CTG GTC 4342 TTT GGC ATT GAC GTG AAG GAA GCA GAC CCC ACC GGC CAC TCC 4384 TAT GTC CTT GTC ACC TGC CTA GGT CTC TCC TAT GAT GGC CTG 4426 CTG GGT GAT AAT CAG ATC ATG CCC AAG ACA GGC TTC CTG ATA 4468 ATT GTC CTG GTC ATG ATT GCA ATG GAG GGC GGC CAT GCT CCT 4510 GAG GAG GAA ATC TGG GAG GAG CTG AGT GTG ATG GAG GTG TAT 4552 GAT GGG AGG GAG CAC AGT GCC TAT GGG GAG CCC AGG AAG CTG 4594 CTC ACC CAA GAT TTG GTG CAG GAA AAG TAC CTG GAG TAC GGC 4636 AGG TGC CGG ACA GTG ATC CCG CAC GCT ATG AGT TCC TGT GGG 4678 GTC CAA GGG CCC TCG CTG AAA CCA GCT ATG TGA 4711 AAGTCCTTGA GTATGTGATC AAGGTCAGTG CAAGAGTTC 4750 GCTTTTTCTT CCCATCCCTG CGTGAAGCAG CTTTGAGAGA GGAGGAAGAG 4800 GGAGTCTGAG CATGAGTTGC AGCCAAGGCC AGTGGGAGGG GGACTGGGCC 4850 AGTGCACCTT CCAGGGCCGC GTCCAGCAGC TTCCCCTGCC TCGTGTGACA 4900 TGAGGCCCAT TCTTCACTCT GAAGAGAGCG GTCAGTGTTC TCAGTAGTAG 4950 GTTTCTGTTC TATTGGGTGA CTTGGAGATT TATCTTTGTT CTCTTTTGGA 5000 ATTGTTCAAA TGTTTTTTTT TAAGGGATGG TTGAATGAAC TTCAGCATCC 5050 AAGTTTATGA ATGACAGCAG TCACACAGTT CTGTGTATAT AGTTTAAGGG 5100 TAAGAGTCTT GTGTTTTATT CAGATTGGGA AATCCATTCT ATTTTGTGAA 5150 TTGGGATAAT AACAGCAGTG GAATAAGTAC TTAGAAATGT GAAAAATGAG 5200 CAGTAAAATA GATGAGATAA AGAACTAAAG AAATTAAGAG ATAGTCAATT 5250 CTTGCCTTAT ACCTCAGTCT ATTCTGTAAA ATTTTTAAAG ATATATGCAT 5300 ACCTGGATTT CCTTGGCTTC TTTGAGAATG TAAGAGAAAT TAAATCTGAA 5350 TAAAGAATTC TTCCTGTTCA CTGGCTCTTT TCTTCTCCAT GCACTGAGCA 5400 TCTGCTTTTT GGAAGGCCCT GGGTTAGTAG TGGAGATGCT AAGGTAAGCC 5450 AGACTCATAC CCACCCATAG GGTCGTAGAG TCTAGGAGCT GCAGTCACGT 5500 AATCGAGGTG GCAAGATGTC CTCTAAAGAT GTAGGGAAAA GTGAGAGAGG 5550 GGTGAGGGTG TGGGGCTCCG GGTGAGAGTG GTGGAGTGTC AATGCCCTGA 5600 GCTGGGGCAT TTTGGGCTTT GGGAAACTGC AGTTCCTTCT GGGGGAGCTG 5650 ATTGTAATGA TCTTGGGTGG ATCC 5674 (2) INFORMATION FOR SEQUENCE ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4157 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-2 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CCCATCCAGA TCCCCATCCG GGCAGAATCC GGTTCCACCC TTGCCGTGAA 50 CCCAGGGAAG TCACGGGCCC GGATGTGACG CCACTGACTT GCACATTGGA 100 GGTCAGAGGA CAGCGAGATT CTCGCCCTGA GCAACGGCCT GACGTCGGCG 150 GAGGGAAGCA GGCGCAGGCT CCGTGAGGAG GCAAGGTAAG ACGCCGAGGG 200 AGGACTGAGG CGGGCCTCAC CCCAGACAGA GGGCCCCCAA TTAATCCAGC 250 GCTGCCTCTG CTGCCGGGCC TGGACCACCC TGCAGGGGAA GACTTCTCAG 300 GCTCAGTCGC CACCACCTCA CCCCGCCACC CCCCGCCGCT TTAACCGCAG 350 GGAACTCTGG CGTAAGAGCT TTGTGTGACC AGGGCAGGGC TGGTTAGAAG 400 TGCTCAGGGC CCAGACTCAG CCAGGAATCA AGGTCAGGAC CCCAAGAGGG 450 GACTGAGGGC AACCCACCCC CTACCCTCAC TACCAATCCC ATCCCCCAAC 500 ACCAACCCCA CCCCCATCCC TCAAACACCA ACCCCACCCC CAAACCCCAT 550 TCCCATCTCC TCCCCCACCA CCATCCTGGC AGAATCCGGC TTTGCCCCTG 600 CAATCAACCC ACGGAAGCTC CGGGAATGGC GGCCAAGCAC GCGGATCCTG 650 ACGTTCACAT GTACGGCTAA GGGAGGGAAG GGGTTGGGTC TCGTGAGTAT 700 GGCCTTTGGG ATGCAGAGGA AGGGCCCAGG CCTCCTGGAA GACAGTGGAG 750 TCCTTAGGGG ACCCAGCATG CCAGGACAGG GGGCCCACTG TACCCCTGTC 800 TCAAACTGAG CCACCTTTTC ATTCAGCCGA GGGAATCCTA GGGATGCAGA 850 CCCACTTCAG GGGGTTGGGG CCCAGCCTGC GAGGAGTCAA GGGGAGGAAG 900 AAGAGGGAGG ACTGAGGGGA CCTTGGAGTC CAGATCAGTG GCAACCTTGG 950 GCTGGGGGAT CCTGGGCACA GTGGCCGAAT GTGCCCCGTG CTCATTGCAC 1000 CTTCAGGGTG ACAGAGAGTT GAGGGCTGTG GTCTGAGGGC TGGGACTTCA 1050 GGTCAGCAGA GGGAGGAATC CCAGGATCTG CCGGACCCAA GGTGTGCCCC 1100 CTTCATGAGG ACTCCCCATA CCCCCGGCCC AGAAAGAAGG GATGCCACAG 1150 AGTCTGGAAG TAAATTGTTC TTAGCTCTGG GGGAACCTGA TCAGGGATGG 1200 CCCTAAGTGA CAATCTCATT TGTACCACAG GCAGGAGGTT GGGGAACCCT 1250 CAGGGAGATA AGGTGTTGGT GTAAAGAGGA GCTGTCTGCT CATTTCAGGG 1300 GGTTCCCCCT TGAGAAAGGG CAGTCCCTGG CAGGAGTAAA GATGAGTAAC 1350 CCACAGGAGG CCATCATAAC GTTCACCCTA GAACCAAAGG GGTCAGCCCT 1400 GGACAACGCA CGTGGGGTAA CAGGATGTGG CCCCTCCTCA CTTGTCTTTC 1450 CAGATCTCAG GGAGTTGATG ACCTTGTTTT CAGAAGGTGA CTCAGTCAAC 1500 ACAGGGGCCC CTCTGGTCGA CAGATGCAGT GGTTCTAGGA TCTGCCAAGC 1550 ATCCAGGTGG AGAGCCTGAG GTAGGATTGA GGGTACCCCT GGGCCAGAAT 1600 GCAGCAAGGG GGCCCCATAG AAATCTGCCC TGCCCCTGCG GTTACTTCAG 1650 AGACCCTGGG CAGGGCTGTC AGCTGAAGTC CCTCCATTAT CTGGGATCTT 1700 TGATGTCAGG GAAGGGGAGG CCTTGGTCTG AAGGGGCTGG AGTCAGGTCA 1750 GTAGAGGGAG GGTCTCAGGC CCTGCCAGGA GTGGACGTGA GGACCAAGCG 1800 GACTCGTCAC CCAGGACACC TGGACTCCAA TGAATTTGAC ATCTCTCGTT 1850 GTCCTTCGCG GAGGACCTGG TCACGTATGG CCAGATGTGG GTCCCCTCTA 1900 TCTCCTTCTG TACCATATCA GGGATGTGAG TTCTTGACAT GAGAGATTCT 1950 CAAGCCAGCA AAAGGGTGGG ATTAGGCCCT ACAAGGAGAA AGGTGAGGGC 2000 CCTGAGTGAG CACAGAGGGG ACCCTCCACC CAAGTAGAGT GGGGACCTCA 2050 CGGAGTCTGG CCAACCCTGC TGAGACTTCT GGGAATCCGT GGCTGTGCTT 2100 GCAGTCTGCA CACTGAAGGC CCGTGCATTC CTCTCCCAGG AATCAGGAGC 2150 TCCAGGAACC AGGCAGTGAG GCCTTGGTCT GAGTCAGTGC CTCAGGTCAC 2200 AGAGCAGAGG GGACGCAGAC AGTGCCAACA CTGAAGGTTT GCCTGGAATG 2250 CACACCAAGG GCCCCACCCG CCCAGAACAA ATGGGACTCC AGAGGGCCTG 2300 GCCTCACCCT CCCTATTCTC AGTCCTGCAG CCTGAGCATG TGCTGGCCGG 2350 CTGTACCCTG AGGTGCCCTC CCACTTCCTC CTTCAGGTTC TGAGGGGGAC 2400 AGGCTGACAA GTAGGACCCG AGGCACTGGA GGAGCATTGA AGGAGAAGAT 2450 CTGTAAGTAA GCCTTTGTCA GAGCCTCCAA GGTTCAGTTC AGTTCTCACC 2500 TAAGGCCTCA CACACGCTCC TTCTCTCCCC AGGCCTGTGG GTCTTCATTG 2550 CCCAGCTCCT GCCCGCACTC CTGCCTGCTG CCCTGACCAG AGTCATC 2597 ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 2639 GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG 2681 CAG GCT CCT GCT ACT GAG GAG CAG CAG ACC GCT TCT TCC TCT 2723 TCT ACT CTA GTG GAA GTT ACC CTG GGG GAG GTG CCT GCT GCC 2765 GAC TCA CCG AGT CCT CCC CAC AGT CCT CAG GGA GCC TCC AGC 2807 TTC TCG ACT ACC ATC AAC TAC ACT CTT TGG AGA CAA TCC GAT 2849 GAG GGC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGA ATG TTT 2891 CCC GAC CTG GAG TCC GAG TTC CAA GCA GCA ATC AGT AGG AAG 2933 ATG GTT GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC 2975 AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGT GTC CTC 3017 AGA AAT TGC CAG GAC TTC TTT CCC GTG ATC TTC AGC AAA GCC 3059 TCC GAG TAC TTG CAG CTG GTC TTT GGC ATC GAG GTG GTG GAA 3101 GTG GTC CCC ATC AGC CAC TTG TAC ATC CTT GTC ACC TGC CTG 3143 GGC CTC TCC TAC GAT GGC CTG CTG GGC GAC AAT CAG GTC ATG 3185 CCC AAG ACA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA 3227 ATA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG 3269 CTG AGT ATG TTG GAG GTG TTT GAG GGG AGG GAG GAC AGT GTC 3311 TTC GCA CAT CCC AGG AAG CTG CTC ATG CAA GAT CTG GTG CAG 3353 GAA AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT 3395 GCA TGC TAC GAG TTC CTG TGG GGT CCA AGG GCC CTC ATT GAA 3437 ACC AGC TAT GTG AAA GTC CTG CAC CAT ACA CTA AAG ATC GGT 3479 GGA GAA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAA CGG GCT 3521 TTG AGA GAG GGA GAA GAG TGA 3542 GTCTCAGCAC ATGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT 3592 GCACCTTCCA GGGCCCCATC CATTAGCTTC CACTGCCTCG TGTGATATGA 3642 GGCCCATTCC TGCCTCTTTG AAGAGAGCAG TCAGCATTCT TAGCAGTGAG 3692 TTTCTGTTCT GTTGGATGAC TTTGAGATTT ATCTTTCTTT CCTGTTGGAA 3742 TTGTTCAAAT GTTCCTTTTA ACAAATGGTT GGATGAACTT CAGCATCCAA 3792 GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGGG 3842 TAAGAGTCCT GTTTTTTATT CAGATTGGGA AATCCATTCC ATTTTGTGAG 3892 TTGTCACATA ATAACAGCAG TGGAATATGT ATTTGCCTAT ATTGTGAACG 3942 AATTAGCAGT AAAATACATG ATACAAGGAA CTCAAAAGAT AGTTAATTCT 3992 TGCCTTATAC CTCAGTCTAT TATGTAAAAT TAAAAATATG TGTATGTTTT 4042 TGCTTCTTTG AGAATGCAAA AGAAATTAAA TCTGAATAAA TTCTTCCTGT 4092 TCACTGGCTC ATTTCTTTAC CATTCACTCA GCATCTGCTC TGTGGAAGGC 4142 CCTGGTAGTA GTGGG 4157 (2) INFORMATION FOR SEQUENCE ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 662 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-21 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GGATCCCCAT GGATCCAGGA AGAATCCAGT TCCACCCCTG CTGTGAACCC 50 AGGGAAGTCA CGGGGCCGGA TGTGACGCCA CTGACTTGCG CGTTGGAGGT 100 CAGAGAACAG CGAGATTCTC GCCCTGAGCA ACGGCCTGAC GTCGGCGGAG 150 GGAAGCAGGC GCAGGCTCCG TGAGGAGGCA AGGTAAGATG CCGAGGGAGG 200 ACTGAGGCGG GCCTCACCCC AGACAGAGGG CCCCCAATAA TCCAGCGCTG 250 CCTCTGCTGC CAGGCCTGGA CCACCCTGCA GGGGAAGACT TCTCAGGCTC 300 AGTCGCCACC ACCTCACCCC GCCACCCCCC GCCGCTTTAA CCGCAGGGAA 350 CTCTGGTGTA AGAGCTTTGT GTGACCAGGG CAGGGCTGGT TAGAAGTGCT 400 CAGGGCCCAG ACTCAGCCAG GAATCAAGGT CAGGACCCCA AGAGGGGACT 450 GAGGGTAACC CCCCCGCACC CCCACCACCA TTCCCATCCC CCAACACCAA 500 CCCCACCCCC ATCCCCCAAC ACCAAACCCA CCACCATCGC TCAAACATCA 550 ACGGCACCCC CAAACCCCGA TTCCCATCCC CACCCATCCT GGCAGAATCG 600 GAGCTTTGCC CCTGCAATCA ACCCACGGAA GCTCCGGGAA TGGCGGCCAA 650 GCACGCGGAT CC 662 (2) INFORMATION FOR SEQUENCE ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1640 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (ix) FEATURE: (A) NAME/KEY: cDNA MAGE-3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GCCGCGAGGG AAGCCGGCCC AGGCTCGGTG AGGAGGCAAG GTTCTGAGGG 50 GACAGGCTGA CCTGGAGGAC CAGAGGCCCC CGGAGGAGCA CTGAAGGAGA 100 AGATCTGCCA GTGGGTCTCC ATTGCCCAGC TCCTGCCCAC ACTCCCGCCT 150 GTTGCCCTGA CCAGAGTCAT C 171 ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 213 GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG 255 CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT 297 TCT ACT CTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC 339 GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC 381 CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT 423 GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC 465 CCT GAC CTG GAG TCC GAG TTC CAA GCA GCA CTC AGT AGG AAG 507 GTG GCC GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC 549 AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GGG AGT GTC GTC 591 GGA AAT TGG CAG TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT 633 TCC AGT TCC TTG CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA 675 GTG GAC CCC ATC GGC CAC TTG TAC ATC TTT GCC ACC TGC CTG 717 GGC CTC TCC TAC GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG 759 CCC AAG GCA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA 801 AGA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG 843 CTG AGT GTG TTA GAG GTG TTT GAG GGG AGG GAA GAC AGT ATG 885 TTG GGG GAT CCC AAG AAG CTG CTC ACC CAA CAT TTC GTG CAG 927 GAA AAC TAC CTG GAG TAC CGG CAG GTC CCC GGC AGT GAT CCT 969 GCA TGT TAT GAA TTC CTG TGG GGT CCA AGG GCC CTC GTT GAA 1011 ACC AGC TAT GTG AAA GTC CTG CAC CAT ATG GTA AAG ATC AGT 1053 GGA GGA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAG TGG GTT 1095 TTG AGA GAG GGG GAA GAG TGA 1116 GTCTGAGCAC GAGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT 1166 GCACCTTCCG GGGCCGCATC CCTTAGTTTC CACTGCCTCC TGTGACGTGA 1216 GGCCCATTCT TCACTCTTTG AAGCGAGCAG TCAGCATTCT TAGTAGTGGG 1266 TTTCTGTTCT GTTGGATGAC TTTGAGATTA TTCTTTGTTT CCTGTTGGAG 1316 TTGTTCAAAT GTTCCTTTTA ACGGATGGTT GAATGAGCGT CAGCATCCAG 1366 GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGAG 1416 TAAGAGTCTT GttTTTTACT CAAATTgGGA AATCCATTCC ATTTTGTGAA 1466 TTGTGACATA ATAATAGCAG TGGTAAAAGT ATTTGCTTAA AATTGTGAGC 1516 GAATTAGCAA TAACATACAT GAGATAACTC AAGAAATCAA AAGATAGTTG 1566 ATTCTTGCCT TGTACCTCAA TCTATTCTGT AAAATTAAAC AAATATGCAA 1616 ACCAGGATTT CCTTGACTTC TTTG 1640 (2) INFORMATION FOR SEQUENCE ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 943 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-31 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GGATCCTCCA CCCCAGTAGA GTGGGGACCT CACAGAGTCT GGCCAACCCT 50 CCTGACAGTT CTGGGAATCC GTGGCTGCGT TTGCTGTCTG CACATTGGGG 100 GCCCGTGGAT TCCTCTCCCA GGAATCAGGA GCTCCAGGAA CAAGGCAGTG 150 AGGACTTGGT CTGAGGCAGT GTCCTCAGGT CACAGAGTAG AGGGGgCTCA 200 GATAGTGCCA ACGGTGAAGG TTTGCCTTGG ATTCAAACCA AGGGCCCCAC 250 CTGCCCCAGA ACACATGGAC TCCAGAGCGC CTGGCCTCAC CCTCAATACT 300 TTCAGTCCTG CAGCCTCAGC ATGCGCTGGC CGGATGTACC CTGAGGTGCC 350 CTCTCACTTC CTCCTTCAGG TTCTGAGGGG ACAGGCTGAC CTGGAGGACC 400 AGAGGCCCCC GGAGGAGCAC TGAAGGAGAA GATCTGTAAG TAAGCCTTTG 450 TTAGAGCCTC CAAGGTTCCA TTCAGTACTC AGCTGAGGTC TCTCACATGC 500 TCCCTCTCTC CCCAGGCCAG TGGGTCTCCA TTGCCCAGCT CCTGCCCACA 550 CTCCCGCCTG TTGCCCTGAC CAGAGTCATC 580 ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 622 GGC CTT GAG GCC CGA GGA GAg GCC CTG GGC CTG GTG GGT GCG 664 CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT 706 TCT AGT GTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC 748 GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC 790 CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT 832 GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC 874 CCT GAC CTG GAG TCT GAG TTC CAA GCA GCA CTC AGT AGG AAG 916 GTG GCC AAG TTG GTT CAT TTT CTG CTC 943 2) INFORMATION FOR SEQUENCE ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-4 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50 GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100 TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150 GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200 TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250 GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300 CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350 CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400 CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450 TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500 TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550 TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600 CCTGCTGCCC TGACCAGAGT CATC 624 ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666 GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCA 708 CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750 TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792 GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834 GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876 AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918 TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960 AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002 GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044 ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086 GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128 GAA GTG GAC CCC GCC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170 CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212 TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254 GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296 GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338 GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380 CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422 CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464 GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506 AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548 GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578 GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628 ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678 CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728 TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778 GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828 TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878 AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928 GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978 GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028 GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078 CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128 ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178 AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228 GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278 CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328 GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378 AACTGCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428 AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478 TCTGAGCAGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528 GGG 2531 (2) INFORMATION FOR SEQUENCE ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-41 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50 GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100 TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150 GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200 TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250 GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300 CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350 CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400 CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450 TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500 TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550 TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600 CCTGCTGCCC TGAGCAGAGT CATC 624 ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666 GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCG 708 CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750 TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792 GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834 GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876 AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918 TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960 AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002 GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044 ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086 GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128 GAA GTG GAC CCC ACC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170 CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212 TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254 GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296 GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338 GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380 CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422 CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464 GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506 AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548 GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578 GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628 ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678 CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728 TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778 GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828 TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878 AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928 GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978 GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028 GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078 CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128 ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178 AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228 GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278 CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328 GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378 AACTCCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428 AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478 TCTGAGCGGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528 GGG 2531 (2) INFORMATION FOR SEQUENCE ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1068 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (ix) FEATURE: (A) NAME/KEY: cDNA MAGE-4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: G GGG CCA AGC ACC TCG CCT GAC GCA GAG TCC TTG TTC CGA 40 GAA GCA CTC AGT AAC AAG GTG GAT GAG TTG GCT CAT TTT CTG 82 CTC CGC AAG TAT CGA GCC AAG GAG CTG GTC ACA AAG GCA GAA 124 ATG CTG GAG AGA GTC ATC AAA AAT TAC AAG CGC TGC TTT CCT 166 GTG ATC TTC GGC AAA GCC TCC GAG TCC CTG AAG ATG ATC TTT 208 GGC ATT GAC GTG AAG GAA GTG GAC CCC GCC AGC AAC ACC TAC 250 ACC CTT GTC ACC TGC CTG GGC CTT TCC TAT GAT GGC CTG CTG 292 GGT AAT AAT CAG ATC TTT CCC AAG ACA GGC CTT CTG ATA ATC 334 GTC CTG GGC ACA ATT GCA ATG GAG GGC GAC AGC GCC TCT GAG 376 GAG GAA ATC TGG GAG GAG CTG GGT GTG ATG GGG GTG TAT GAT 418 GGG AGG GAG CAC ACT GTC TAT GGG GAG CCC AGG AAA CTG CTC 460 ACC CAA GAT TGG GTG CAG GAA AAC TAC CTG GAG TAC CGG CAG 502 GTA CCC GGC AGT AAT CCT GCG CGC TAT GAG TTC CTG TGG GGT 544 CCA AGG GCT CTG GCT GAA ACC AGC TAT GTG AAA GTC CTG GAG 586 CAT GTG GTC AGG GTC AAT GCA AGA GTT CGC ATT GCC TAC CCA 628 TCC CTG CGT GAA GCA GCT TTG TTA GAG GAG GAA GAG GGA GTC 670 TGAGCATGAG TTGCAGCCAG GGCTGTGGGG AAGGGGCAGG GCTGGGCCAG 720 TGCATCTAAC AGCCCTGTGC AGCAGCTTCC CTTGCCTCGT GTAACATGAG 770 GCCCATTCTT CACTCTGTTT GAAGAAAATA GTCAGTGTTC TTAGTAGTGG 820 GTTTCTATTT TGTTGGATGA CTTGGAGATT TATCTCTGTT TCCTTTTACA 870 ATTGTTGAAA TGTTCCTTTT AATGGATGGT TGAATTAACT TCAGCATCCA 920 AGTTTATGAA TCGTAGTTAA CGTATATTGC TGTTAATATA GTTTAGGAGT 970 AAGAGTCTTG TTTTTTATTC AGATTGGGAA ATCCGTTCTA TTTTGTGAAT 1020 TTGGGACATA ATAACAGCAG TGGAGTAAGT ATTTAGAAGT GTGAATTC 1068 (2) INFORMATION FOR SEQUENCE ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2226 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-5 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50 GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100 TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150 GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200 TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250 TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300 GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350 TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400 CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450 GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500 ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550 GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600 AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644 ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686 CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 728 GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 770 TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 812 AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 854 CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 896 TGG CTG ACT TGA 908 TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCTGGT CACAAAGGCA 958 GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1008 CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1058 AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1108 CTCCTATGAT GGCCTGCTGG TTGATAATAA TCAGATCATG CCCAAGACGG 1158 GCCTCCTGAT AATCGTCTTG GGCATGATTG CAATGGAGGG CAAATGCGTC 1208 CCTGAGGAGA AAATCTGGGA GGAGCTGAGT GTGATGAAGG TGTATGTTGG 1258 GAGGGAGCAC AGTGTCTGTG GGGAGCCCAG GAAGCTGCTC ACCCAAGATT 1308 TGGTGCAGGA AAACTACCTG GAGTACCGGC AGGTGCCCAG CAGTGATCCC 1358 ATATGCTATG AGTTACTGTG GGGTCCAAGG GCACTCGCTG CTTGAAAGTA 1408 CTGGAGCACG TGGTCAGGGT CAATGCAAGA GTTCTCATTT CCTACCCATC 1458 CCTGCGTGAA GCAGCTTTGA GAGAGGAGGA AGAGGGAGTC TGAGCATGAG 1508 CTGCAGCCAG GGCCACTGCG AGGGGGGCTG GGCCAGTGCA CCTTCCAGGG 1558 CTCCGTCCAG TAGTTTCCCC TGCCTTAATG TGACATGAGG CCCATTCTTC 1608 TCTCTTTGAA GAGAGCAGTC AACATTCTTA GTAGTGGGTT TCTGTTCTAT 1658 TGGATGACTT TGAGATTTGT CTTTGTTTCC TTTTGGAATT GTTCAAATGT 1708 TTCTTTTAAT GGGTGGTTGA ATGAACTTCA GCATTCAAAT TTATGAATGA 1758 CAGTAGTCAC ACATAGTGCT GTTTATATAG TTTAGGAGTA AGAGTCTTGT 1808 TTTTTATTCA GATTGGGAAA TCCATTCCAT TTTGTGAATT GGGACATAGT 1858 TACAGCAGTG GAATAAGTAT TCATTTAGAA ATGTGAATGA GCAGTAAAAC 1908 TGATGACATA AAGAAATTAA AAGATATTTA ATTCTTGCTT ATACTCAGTC 1958 TATTCGGTAA AATTTTTTTT AAAAAATGTG CATACCTGGA TTTCCTTGGC 2008 TTCTTTGAGA ATGTAAGACA AATTAAATCT GAATAAATCA TTCTCCCTGT 2058 TCACTGGCTC ATTTATTCTC TATGCACTGA GCATTTGCTC TGTGGAAGGC 2108 CCTGGGTTAA TAGTGGAGAT GCTAAGGTAA GCCAGACTCA CCCCTACCCA 2158 CAGGGTAGTA AAGTCTAGGA GCAGCAGTCA TATAATTAAG GTGGAGAGAT 2208 GCCCTCTAAG ATGTAGAG 2226 (2) INFORMATION FOR SEQUENCE ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2305 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-51 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50 GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100 TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150 GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200 TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250 TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300 GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350 TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400 CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450 GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500 ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550 GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600 AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644 ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686 GGC CTT GAC ACC CAA GAA GAG CCC TGG GCC TGG TGG GTG TGC 728 AGG CTG CCA CTA CTG AGG AGC AGG AGG CTG TGT CCT CCT CCT 770 CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 812 GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 854 TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 896 AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 938 CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 980 TGG CTG ACT TGA 992 TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCCGGT CACAAAGGCA 1042 GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1092 CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1142 AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1192 CTCCTATGAT GGCCTGGTGG TTTAATCAGA TCATGCCCAA GACGGGCCTC 1242 CTGATAATCG TCTTGGGCAT GATTGCAATG GAGGGCAAAT GCGTCCCTGA 1292 GGAGAAAATC TGGGAGGAGC TGGGTGTGAT GAAGGTGTAT GTTGGGAGGG 1342 AGCACAGTGT CTGTGGGGAG CCCAGGAAGC TGCTCACCCA AGATTTGGTG 1392 CAGGAAAACT ACCTGGAGTA CCGCAGGTGC CCAGCAGTGA TCCCATATGC 1442 TATGAGTTAC TGTGGGGTCC AAGGGCACTC GCTGCTTGAA AGTACTGGAG 1492 CACGTGGTCA GGGTCAATGC AAGAGTTCTC ATTTCCTACC CATCCCTGCA 1542 TGAAGCAGCT TTGAGAGAGG AGGAAGAGGG AGTCTGAGCA TGAGCTGCAG 1592 CCAGGGCCAC TGCGAGGGGG GCTGGGCCAG TGCACCTTCC AGGGCTCCGT 1642 CCAGTAGTTT CCCCTGCCTT AATGTGACAT GAGGCCCATT CTTCTCTCTT 1692 TGAAGAGAGC AGTCAACATT CTTAGTAGTG GGTTTCTGTT CTATTGGATG 1742 ACTTTGAGAT TTGTCTTTGT TTCCTTTTGG AATTGTTCAA ATGTTCCTTT 1792 TAATGGGTGG TTGAATGAAC TTCAGCATTC AAATTTATGA ATGACAGTAG 1842 TCACACATAG TGCTGTTTAT ATAGTTTAGG AGTAAGAGTC TTGTTTTTTA 1892 TTCAGATTGG GAAATCCATT CCATTTTGTG AATTGGGACA TAGTTACAGC 1942 AGTGGAATAA GTATTCATTT AGAAATGTGA ATGAGCAGTA AAACTGATGA 1992 GATAAAGAAA TTAAAAGATA TTTAATTCTT GCCTTATACT CAGTCTATTC 2042 GGTAAAATTT TTTTTTAAAA ATGTGCATAC CTGGATTTCC TTGGCTTCTT 2092 TGAGAATGTA AGACAAATTA AATCTGAATA AATCATTCTC CCTGTTCACT 2142 GGCTCATTTA TTCTCTATGC ACTGAGCATT TGCTCTGTGG AAGGCCCTGG 2192 GTTAATAGTG GAGATGCTAA GGTAAGCCAG ACTCACCCCT ACCCACAGGG 2242 TAGTAAAGTC TAGGAGCAGC AGTCATATAA TTAAGGTGGA GAGATGCCCT 2292 CTAAGATGTA GAG 2305 (2) INFORMATION FOR SEQUENCE ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: MAGE-6 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT TCC GAT TCC TTG 42 CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA GTG GAC CCC ATC 84 GGC CAC GTG TAC ATC TTT GCC ACC TGC CTG GGC CTC TCC TAC 126 GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG CCC AGG ACA GGC 168 TTC CTG ATA ATC ATC CTG GCC ATA ATC GCA AGA GAG GGC GAC 210 TGT GCC CCT GAG GAG 225 (2) INFORMATION FOR SEQUENCE ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1947 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-7 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: TGAATGGACA ACAAGGGCCC CACACTCCCC AGAACACAAG GGACTCCAGA 50 GAGCCCAGCC TCACCTTCCC TACTGTCAGT CCTGCAGCCT CAGCCTCTGC 100 TGGCCGGCTG TACCCTGAGG TGCCCTCTCA CTTCCTCCTT CAGGTTCTCA 150 GCGGACAGGC CGGCCAGGAG GTCAGAAGCC CCAGGAGGCC CCAGAGGAGC 200 ACCGAAGGAG AAGATCTGTA AGTAGGCCTT TGTTAGGGCC TCCAGGGCGT 250 GGTTCACAAA TGAGGCCCCT CACAAGCTCC TTCTCTCCCC AGATCTGTGG 300 GTTCCTCCCC ATCGCCCAGC TGCTGCCCGC ACTCCAGCCT GCTGCCCTGA 350 CCAGAGTCAT CATGTCTTCT GAGCAGAGGA GTCAGCACTG CAAGCCTGAG 400 GATGCCTTGA GGCCCAAGGA CAGGAGGCTC TGGGCCTGGT GGGTGCGCAG 450 GCTCCCGCCA CCGAGGAGCA CGAGGCTGCC TCCTCCTTCA CTCTGATTGA 500 AGGCACCCTG GAGGAGGTGC CTGCTGCTGG GTCCCCCAGT CCTCCCCTGA 550 GTCTCAGGGT TCCTCCTTTT CCCTGACCAT CAGCAACAAC ACTCTATGGA 600 GCCAATCCAG TGAGGGCACC AGCAGCCGGG AAGAGGAGGG GCCAACCACC 650 TAGACACACC CCGCTCACCT GGCGTCCTTG TTCCA 685 ATG GGA AGG TGG CTG AGT TGG TTC GCT TCC TGC TGC ACA AGT 727 ATC GAG TCA AGG AGC TGG TCA CAA AGG CAG AAA TGC TGG ACA 769 GTG TCA TCA AAA ATT ACA AGC ACT AGT TTC CTT GTG ATC TAT 811 GGC AAA GCC TCA GAG TGC ATG CAG GTG ATG TTT GGC ATT GAC 853 ATG AAG GAA GTG GAC CCC GCG GCC ACT CCT ACG TCC TTG TCA 895 CCT GCT TGG GCC TCT CCT ACA ATG GCC TGC TGG GTG ATG ATC 937 AGA GCA TGC CCG AGA CCG GCC TTC TGA 964 TTATGGTCTT GACCATGATC TTAATGGAGG GCCACTGTGC CCCTGAGGAG 1014 GCAATCTGGG AAGCGTTGAG TGTAATGGTG TATGATGGGA TGGAGCAGTT 1064 TCTTTGGGCA GCTGAGGAAG CTGCTCACCC AAGATTGGGT GCAGGAAAAC 1114 TACCTGCAAT ACCGCCAGGT GCCCAGCAGT GATCCCCCGT GCTACCAGTT 1164 CCTGTGGGGT CCAAGGGCCC TCATTGAAAC CAGCTATGTG AAAGTCCTGG 1214 AGTATGCAGC CAGGGTCAGT ACTAAAGAGA GCATTTCCTA CCCATCCCTG 1264 CATGAAGAGG CTTTGGGAGA GGAGGAAGAG GGAGTCTGAG CAGAAGTTGC 1314 AGCCAGGGCC AGTGGGGCAG ATTGGGGGAG GGCCTGGGCA GTGCACGTTC 1364 CACACATCCA CCACCTTCCC TGTCCTGTTA CATGAGGCCC ATTCTTCACT 1414 CTGTGTTTGA AGAGAGCAGT CAATGTTCTC AGTAGCGGGG AGTGTGTTGG 1464 GTGTGAGGGA ATACAAGGTG GACCATCTCT CAGTTCCTGT TCTCTTGGGC 1514 GATTTGGAGG TTTATCTTTG TTTCCTTTTG CAGTCGTTCA AATGTTCCTT 1564 TTAATGGATG GTGTAATGAA CTTCAACATT CATTTCATGT ATGACAGTAG 1614 GCAGACTTAC TGTTTTTTAT ATAGTTAAAA GTAAGTGCAT TGTTTTTTAT 1664 TTATGTAAGA AAATCTATGT TATTTCTTGA ATTGGGACAA CATAACATAG 1714 CAGAGGATTA AGTACCTTTT ATAATGTGAA AGAACAAAGC GGTAAAATGG 1764 GTGAGATAAA GAAATAAAGA AATTAAATTG GCTGGGCACG GTGGCTCACG 1814 CCTGTAATCC CAGCACTTTA GGAGGCAGAG GCACGGGGAT CACGAGGTCA 1864 GGAGATCGAG ACCATTCTGG CTAACACAGT GAAACACCAT CTCTATTAAA 1914 AATACAAAAC TTAGCCGGGC GTGGTGGCGG GTG 1947 (2) INFORMATION FOR SEQUENCE ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1810 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-8 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: GAGCTCCAGG AACCAGGCTG TGAGGTCTTG GTCTGAGGCA GTATCTTCAA 50 TCACAGAGCA TAAGAGGCCC AGGCAGTAGT AGCAGTCAAG CTGAGGTGGT 100 GTTTCCCCTG TATGTATACC AGAGGCCCCT CTGGCATCAG AACAGCAGGA 150 ACCCCACAGT TCCTGGCCCT ACCAGCCCTT TTGTCAGTCC TGGAGCCTTG 200 GCCTTTGCCA GGAGGCTGCA CCCTGAGATG CCCTCTCAAT TTCTCCTTCA 250 GGTTCGCAGA GAACAGGCCA GCCAGGAGGT CAGGAGGCCC CAGAGAAGCA 300 CTGAAGAAGA CCTGTAAGTA GACCTTTGTT AGGGCATCCA GGGTGTAGTA 350 CCCAGCTGAG GCCTCTCACA CGCTTCCTCT CTCCCCAGGC CTGTGGGTCT 400 CAATTGCCCA GCTCCGGCCC ACACTCTCCT GCTGCCCTGA CCTGAGTCAT 450 C 451 O 96/10413 PCIYUS95/12463 48 ATG CTT CTT GGG CAG AAG AGT CAG CGC TAC AAG GCT GAG GAA 493 GGC CTT CAG GCC CAA GGA GAG GCA CCA GGG CTT ATG GAT GTG 535 CAG ATT CCC ACA GCT GAG GAG CAG AAG GCT GCA TCC TCC TCC 577 TCT ACT CTG ATC ATG GGA ACC CTT GAG GAG GTG ACT GAT TCT 619 GGG TCA CCA AGT CCT CCC CAG AGT CCT GAG GGT GCC TCC TCT 661 TCC CTG ACT GTC ACC GAC AGC ACT CTG TGG AGC CAA TCC GAT 703 GAG GGT TCC AGC AGC AAT GAA GAG GAG GGG CCA AGC ACC TCC 745 CCG GAC CCA GCT CAC CTG GAG TCC CTG TTC CGG GAA GCA CTT 787 GAT GAG AAA GTG GCT GAG TTA GTT CGT TTC CTG CTC CGC AAA 829 TAT CAA ATT AAG GAG CCG GTC ACA AAG GCA GAA ATG CTT GAG 871 AGT GTC ATC AAA AAT TAC AAG AAC CAC TTT CCT GAT ATC TTC 913 AGC AAA GCC TCT GAG TGC ATG CAG GTG ATC TTT GGC ATT GAT 955 GTG AAG GAA GTG GAC CCT GCC GGC CAC TCC TAC ATC CTT GTC 997 ACC TGC CTG GGC CTC TCC TAT GAT GGC CTG CTG GGT GAT GAT 1039 CAG AGT ACG CCC AAG ACC GGC CTC CTG ATA ATC GTC CTG GGC 1081 ATG ATC TTA ATG GAG GGC AGC CGC GCC CCG GAG GAG GCA ATC 1123 TGG GAA GCA TTG AGT GTG ATG GGG GCT GTA TGA 1156 TGGGAGGGAG CACAGTGTCT ATTGGAAGCT CAGGAAGCTG CTCACCCAAG 1206 AGTGGGTGCA GGAGAACTAC CTGGAGTACC GCCAGGCGCC CGGCAGTGAT 1256 CCTGTGCGCT ACGAGTTCCT GTGGGGTCCA AGGGCCCTTG CTGAAACCAG 1306 CTATGTGAAA GTCCTGGAGC ATGTGGTCAG GGTCAATGCA AGAGTTCGCA 1356 TTTCCTACCC ATCCCTGCAT GAAGAGGCTT TGGGAGAGGA GAAAGGAGTT 1406 TGAGCAGGAG TTGCAGCTAG GGCCAGTGGG GCAGGTTGTG GGAGGGCCTG 1456 GGCCAGTGCA CGTTCCAGGG CCACATCCAC CACTTTCCCT GCTCTGTTAC 1506 ATGAGGCCCA TTCTTCACTC TGTGTTTGAA GAGAGCAGTC ACAGTTCTCA 1556 GTAGTGGGGA GCATGTTGGG TGTGAGGGAA CACAGTGTGG ACCATCTCTC 1606 AGTTCCTGTT CTATTGGGCG ATTTGGAGGT TTATCTTTGT TTCCTTTTGG 1656 AATTGTTCCA ATGTTCCTTC TAATGGATGG TGTAATGAAC TTCAACATTC 1706 ATTTTATGTA TGACAGTAGA CAGACTTACT GCTTTTTATA TAGTTTAGGA 1756 GTAAGAGTCT TGCTTTTCAT TTATACTGGG AAACCCATGT TATTTCTTGA 1806 ATTC 1810 (2) INFORMATION FOR SEQUENCE ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1412 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-9 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: TCTGAGACAG TGTCCTCAGG TCGCAGAGCA GAGGAGACCC AGGCAGTGTC 50 AGCAGTGAAG GTGAAGTGTT CACCCTGAAT GTGCACCAAG GGCCCCACCT 100 GCCCCAGCAC ACATGGGACC CCATAGCACC TGGCCCCATT CCCCCTACTG 150 TCACTCATAG AGCCTTGATC TCTGCAGGCT AGCTGCACGC TGAGTAGCCC 200 TCTCACTTCC TCCCTCAGGT TCTCGGGACA GGCTAACCAG GAGGACAGGA 250 GCCCCAAGAG GCCCCAGAGC AGCACTGACG AAGACCTGTA AGTCAGCCTT 300 TGTTAGAACC TCCAAGGTTC GGTTCTCAGC TGAAGTCTCT CACACACTCC 350 CTCTCTCCCC AGGCCTGTGG GTCTCCATCG CCCAGCTCCT GCCCACGCTC 400 CTGACTGCTG CCCTGACCAG AGTCATC 427 ATG TCT CTC GAG CAG AGG AGT CCG CAC TGC AAG CCT GAT GAA 469 GAC CTT GAA GCC CAA GGA GAG GAC TTG GGC CTG ATG GGT GCA 511 CAG GAA CCC ACA GGC GAG GAG GAG GAG ACT ACC TCC TCC TCT 553 GAC AGC AAG GAG GAG GAG GTG TCT GCT GCT GGG TCA TCA AGT 595 CCT CCC CAG AGT CCT CAG GGA GGC GCT TCC TCC TCC ATT TCC 637 GTC TAC TAC ACT TTA TGG AGC CAA TTC GAT GAG GGC TCC AGC 679 AGT CAA GAA GAG GAA GAG CCA AGC TCC TCG GTC GAC CCA GCT 721 CAG CTG GAG TTC ATG TTC CAA GAA GCA CTG AAA TTG AAG GTG 763 GCT GAG TTG GTT CAT TTC CTG CTC CAC AAA TAT CGA GTC AAG 805 GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGC GTC ATC AAA 847 AAT TAC AAG CGC TAC TTT CCT GTG ATC TTC GGC AAA GCC TCC 889 GAG TTC ATG CAG GTG ATC TTT GGC ACT GAT GTG AAG GAG GTG 931 GAC CCC GCC GGC CAC TCC TAC ATC CTT GTC ACT GCT CTT GGC 973 CTC TCG TGC GAT AGC ATG CTG GGT GAT GGT CAT AGC ATG CCC 1015 AAG GCC GCC CTC CTG ATC ATT GTC CTG GGT GTG ATC CTA ACC 1057 AAA GAC AAC TGC GCC CCT GAA GAG GTT ATC TGG GAA GCG TTG 1099 AGT GTG ATG GGG GTG TAT GTT GGG AAG GAG CAC ATG TTC TAC 1141 GGG GAG CCC AGG AAG CTG CTC ACC CAA GAT TGG GTG CAG GAA 1183 AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT GCG 1225 CAC TAC GAG TTC CTG TGG GGT TCC AAG GCC CAC GCT GAA ACC 1267 AGC TAT GAG AAG GTC ATA AAT TAT TTG GTC ATG CTC AAT GCA 1309 AGA GAG CCC ATC TGC TAC CCA TCC CTT TAT GAA GAG GTT TTG 1351 GGA GAG GAG CAA GAG GGA GTC TGA 1375 GCACCAGCCG CAGCCGGGGC CAAAGTTTGT GGGGTCA 1412 (2) INFORMATION FOR SEQUENCE ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 920 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-10 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: ACCTGCTCCA GGACAAAGTG GACCCCACTG CATCAGCTCC ACCTACCCTA 50 CTGTCAGTCC TGGAGCCTTG GCCTCTGCCG GCTGCATCCT GAGGAGCCAT 100 CTCTCACTTC CTTCTTCAGG TTCTCAGGGG ACAGGGAGAG CAAGAGGTCA 150 AGAGCTGTGG GACACCACAG AGCAGCACTG AAGGAGAAGA CCTGTAAGTT 200 GGCCTTTGTT AGAACCTCCA GGGTGTGGTT CTCAGCTGTG GCCACTTACA 250 CCCTCCCTCT CTCCCCAGGC CTGTGGGTCC CCATCGCCCA AGTCCTGCCC 300 ACACTCCCAC CTGCTACCCT GATCAGAGTC ATC 333 ATG CCT CGA GCT CCA AAG CGT CAG CGC TGC ATG CCT GAA GAA 375 GAT CTT CAA TCC CAA AGT GAG ACA CAG GGC CTC GAG GGT GCA 417 CAG GCT CCC CTG GCT GTG GAG GAG GAT GCT TCA TCA TCC ACT 459 TCC ACC AGC TCC TCT TTT CCA TCC TCT TTT CCC TCC TCC TCC 501 TCT TCC TCC TCC TCC TCC TGC TAT CCT CTA ATA CCA AGC ACC 543 CCA GAG GAG GTT TCT GCT GAT GAT GAG ACA CCA AAT CCT CCC 585 CAG AGT GCT CAG ATA GCC TGC TCC TCC CCC TCG GTC GTT GCT 627 TCC CTT CCA TTA GAT CAA TCT GAT GAG GGC TCC AGC AGC CAA 669 AAG GAG GAG AGT CCA AGC ACC CTA CAG GTC CTG CCA GAC AGT 711 GAG TCT TTA CCC AGA AGT GAG ATA GAT GAA AAG GTG ACT GAT 753 TTG GTG CAG TTT CTG CTC TTC AAG TAT CAA ATG AAG GAG CCG 795 ATC ACA AAG GCA GAA ATA CTG GAG AGT GTC ATA AAA AAT TAT 837 GAA GAC CAC TTC CCT TTG TTG TTT AGT GAA GCC TCC GAG TGC 879 ATG CTG CTG GTC TTT GGC ATT GAT GTA AAG GAA GTG GAT CC 920 (2) INFORMATION FOR SEQUENCE ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1107 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-11 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: AGAGAACAGG CCAACCTGGA GGACAGGAGT CCCAGGAGAA CCCAGAGGAT 50 CACTGGAGGA GAACAAGTGT AAGTAGGCCT TTGTTAGATT CTCCATGGTT 100 CATATCTCAT CTGAGTCTGT TCTCACGCTC CCTCTCTCCC CAGGCTGTGG 150 GGCCCCATCA CCCAGATATT TCCCACAGTT CGGCCTGCTG ACCTAACCAG 200 AGTCATCATG CCTCTTGAGC AAAGAAGTCA GCACTGCAAG CCTGAGGAAG 250 CCTTCAGGCC CAAGAAGAAG ACCTGGGCCT GGTGGGTGCA CAGGCTCTCC 300 AAGCTGAGGA GCAGGAGGCT GCCTTCTTCT CCTCTACTCT GAATGTGGGC 350 ACTCTAGAGG AGTTGCCTGC TGCTGAGTCA CCAAGTCCTC CCCAGAGTCC 400 TCAGGAAGAG TCCTTCTCTC CCACTGCCAT GGATGCCATC TTTGGGAGCC 450 TATCTGATGA GGGCTCTGGC AGCCAAGAAA AGGAGGGGCC AAGTACCTCG 500 CCTGACCTGA TAGACCCTGA GTCCTTTTCC CAAGATATAC TACATGACAA 550 GATAATTGAT TTGGTTCATT TATTCTCCGC AAGTATCGAG TCAAGGGGCT 600 GATCACAAAG GCAGAA 616 ATG CTG GGG AGT GTC ATC AAA AAT TAT GAG GAC TAC TTT CCT 658 GAG ATA TTT AGG GAA GCC TCT GTA TGC ATG CAA CTG CTC TTT 700 GGC ATT GAT GTG AAG GAA GTG GAC CCC ACT AGC CAC TCC TAT 742 GTC CTT GTC ACC TCC CTC AAC CTC TCT TAT GAT GGC ATA CAG 784 TGT AAT GAG CAG AGC ATG CCC AAG TCT GGC CTC CTG ATA ATA 826 GTC CTG GGT GTA ATC TTC ATG GAG GGG AAC TGC ATC CCT GAA 868 GAG GTT ATG TGG GAA GTC CTG AGC ATT ATG GGG GTG TAT GCT 910 GGA AGG GAG CAC TTC CTC TTT GGG GAG CCC AAG AGG CTC CTT 952 ACC CAA AAT TGG GTG CAG GAA AAG TAC CTG GTG TAC CGG CAG 994 GTG CCC GGC ACT GAT CCT GCA TGC TAT GAG TTC CTG TGG GGT 1036 CCA AGG GCC CAC GCT GAG ACC AGC AAG ATG AAA GTT CTT GAG 1078 TAC ATA GCC AAT GCC AAT GGG AGG GAT CC 1107 (2) INFORMATION FOR SEQUENCE ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2150 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: smage-I (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TCTGTCTGCA TATGCCTCCA CTTGTGTGTA GCAGTCTCAA ATGGATCTCT 50 CTCTACAGAC CTCTGTCTGT GTCTGGCACC CTAAGTGGCT TTGCATGGGC 100 ACAGGTTTCT GCCCCTGCAT GGAGCTTAAA TAGATCTTTC TCCACAGGCC 150 TATACCCCTG CATTGTAAGT TTAAGTGGCT TTATGTGGAT ACAGGTCTCT 200 GCCCTTGTAT GCAGGCCTAA GTTTTTCTGT CTGCTTAACC CCTCCAAGTG 250 AAGCTAGTGA AAGATCTAAC CCACTTTTGG AAGTCTGAAA CTAGACTTTT 300 ATGCAGTGGC CTAACAAGTT TTAATTTCTT CCACAGGGTT TGCAGAAAAG 350 AGCTTGATCC ACGAGTTCAG AAGTCCTGGT ATGTTCCTAG AAAG 394 ATG TTC TCC TGG AAA GCT TCA AAA GCC AGG TCT CCA TTA AGT 436 CCA AGG TAT TCT CTA CCT GGT AGT ACA GAG GTA CTT ACA GGT 478 TGT CAT TCT TAT CCT TCC AGA TTC CTG TCT GCC AGC TCT TTT 520 ACT TCA GCC CTG AGC ACA GTC AAC ATG CCT AGG GGT CAA AAG 562 AGT AAG ACC CGC TCC CGT GCA AAA CGA CAG CAG TCA CGC AGG 604 GAG GTT CCA GTA GTT CAG CCC ACT GCA GAG GAA GCA GGG TCT 646 TCT CCT GTT GAC CAG AGT GCT GGG TCC AGC TTC CCT GGT GGT 688 TCT GCT CCT CAG GGT GTG AAA ACC CCT GGA TCT TTT GGT GCA 730 GGT GTA TCC TGC ACA GGC TCT GGT ATA GGT GGT AGA AAT GCT 772 GCT GTC CTG CCT GAT ACA AAA AGT TCA GAT GGC ACC CAG GCA 814 GGG ACT TCC ATT CAG CAC ACA CTG AAA GAT CCT ATC ATG AGG 856 AAG GCT AGT GTG CTG ATA GAA TTC CTG CTA GAT AAA TTT AAG 898 ATG AAA GAA GCA GTT ACA AGG AGT GAA ATG CTG GCA GTA GTT 940 AAC AAG AAG TAT AAG GAG CAA TTC CCT GAG ATC CTC AGG AGA 982 ACT TCT GCA CGC CTA GAA TTA GTC TTT GGT CTT GAG TTG AAG 1024 GAA ATT GAT CCC AGC ACT CAT TCC TAT TTG CTG GTA GGC AAA 1066 CTG GGT CTT TCC ACT GAG GGA AGT TTG AGT AGT AAC TGG GGG 1108 TTG CCT AGG ACA GGT CTC CTA ATG TCT GTC CTA GGT GTG ATC 1150 TTC ATG AAG GGT AAC CGT GCC ACT GAG CAA GAG GTC TGG CAA 1192 TTT CTG CAT GGA GTG GGG GTA TAT GCT GGG AAG AAG CAC TTG 1234 ATC TTT GGC GAG CCT GAG GAG TTT ATA AGA GAT GTA GTG CGG 1276 GAA AAT TAC CTG GAG TAC CGC CAG GTA CCT GGC AGT GAT CCC 1318 CCA AGC TAT GAG TTC CTG TGG GGA CCC AGA GCC CAT GCT GAA 1360 ACA ACC AAG ATG AAA GTC CTG GAA GTT TTA GCT AAA GTC AAT 1402 GGC ACA GTC CCT AGT GCC TTC CCT AAT CTC TAC CAG TTG GCT 1444 CTT AGA GAT CAG GCA GGA GGG GTG CCA AGA AGG AGA GTT CAA 1486 GGC AAG GGT GTT CAT TCC AAG GCC CCA TCC CAA AAG TCC TCT 1528 AAC ATG TAG 1537 TTGAGTCTGT TCTGTTGTGT TTGAAAAACA GTCAGGCTCC TAATCAGTAG 1587 AGAGTTCATA GCCTACCAGA ACCAACATGC ATCCATTCTT GGCCTGTTAT 1637 ACATTAGTAG AATGGAGGCT ATTTTTGTTA CTTTTCAAAT GTTTGTTTAA 1687 CTAAACAGTG CTTTTTGCCA TGCTTCTTGT TAACTGCATA AAGAGGTAAC 1737 TGTCACTTGT CAGATTAGGA CTTGTTTTGT TATTTGCAAC AAACTGGAAA 1787 ACATTATTTT GTTTTTACTA AAACATTGTG TAACATTGCA TTGGAGAAGG 1837 GATTGTCATG GCAATGTGAT ATCATACAGT GGTGAAACAA CAGTGAAGTG 1887 GGAAAGTTTA TATTGTTAAT TTTGAAAATT TTATGAGTGT GATTGCTGTA 1937 TACTTTTTTC TTTTTTGTAT AATGCTAAGT GAAATAAAGT TGGATTTGAT 1987 GACTTTACTC AAATTCATTA GAAAGTAAAT CGTAAAACTC TATTACTTTA 2037 TTATTTTCTT CAATTATGAA TTAAGCATTG GTTATCTGGA AGTTTCTCCA 2087 GTAGCACAGG ATCTAGTATG AAATGTATCT AGTATAGGCA CTGACAGTGA 2137 GTTATCAGAG TCT 2150 (2) INFORMATION FOR SEQUENCE ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2099 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: smage-II (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: ACCTTATTGG GTCTGTCTGC ATATGCCTCC ACTTGTGTGT AGCAGTCTCA 50 AATGGATCTC TCTCTACAGA CCTCTGTCTG TGTCTGGCAC CCTAAGTGGC 100 TTTGCATGGG CACAGGTTTC TGCCCCTGCA TGGAGCTTAA ATAGATCTTT 150 CTCCACAGGC CTATACCCCT GCATTGTAAG TTTAAGTGGC TTTATGTGGA 200 TACAGGTCTC TGCCCTTGTA TGCAGGCCTA AGTTTTTCTG TCTGCTTAGC 250 CCCTCCAAGT GAAGCTAGTG AAAGATCTAA CCCACTTTTG GAAGTCTGAA 300 ACTAGACTTT TATGCAGTGG CCTAACAAGT TTTAATTTCT TCCACAGGGT 350 TTGCAGAAAA GAGCTTGATC CACGAGTTCG GAAGTCCTGG TATGTTCCTA 400 GAAAGATGTT CTCCTGGAAA GCTTCAAAAG CCAGGTCTCC ATTAAGTCCA 450 AGGTATTCTC TACCTGGTAG TACAGAGGTA CTTACAGGTT GTCATTCTTA 500 TCTTTCCAGA TTCCTGTCTG CCAGCTCTTT TACTTCAGCC CTGAGCACAG 550 TCAACATGCC TAGGGGTCAA AAGAGTAAGA CCCGCTCCCG TGCAAAACGA 600 CAGCAGTCAC GCAGGGAGGT TCCAGTAGTT CAGCCCACTG CAGAGGAAGC 650 AGGGTCTTCT CCTGTTGACC AGAGTGCTGG GTCCAGCTTC CCTGGTGGTT 700 CTGCTCCTCA GGGTGTGAAA ACCCCTGGAT CTTTTGGTGC AGGTGTATCC 750 TGCACAGGCT CTGGTATAGG TGGTAGAAAT GCTGCTGTCC TGCCTGATAC 800 AAAAAGTTCA GATGGCACCC AGGCAGGGAC TTCCATTCAG CACACACTGA 850 AAGATCCTAT CATGAGGAAG GCTAGTGTGC TGATAGAATT CCTGCTAGAT 900 AAGTTTAAGA TGAAAGAAGC AGTTACAAGG AGTGAAATGC TGGCAGTAGT 950 TAACAAGAAG TATAAGGAGC AATTCCCTGA GATCCTCAGG AGAACTTCTG 1000 CACGCCTAGA ATTAGTCTTT GGTCTTGAGT TGAAGGAAAT TGATCCCAGC 1050 ACTCATTCCT ATTTGCTGGT AGGCAAACTG GGTCTTTCCA CTGAGGGAAG 1100 TTTGAGTAGT AACTGGGGGT TGCCTAGGAC AGGTCTCCTA ATGTCTGTCC 1150 TAGGTGTGAT CTTCATGAAG GGTAACCGTG CCACTGAGCA AGAGGTCTGG 1200 CAATTTCTGC ATGGAGTGGG GGTATATGCT GGGAAGAAGC ACTTGATCTT 1250 TGGCGAGCCT GAGGAGTTTA TAAGAGATGT AGTGCGGGAA AATTACCTGG 1300 AGTACCGCCA GGTACCTGGC AGTGATCCCC CAAGCTATGA GTTCCTGTGG 1350 GGACCCAGAG CCCATGCTGA AACAACCAAG ATGAAAGTCC TGGAAGTTTT 1400 AGCTAAAGTC AATGGCACAG TCCCTAGTGC CTTCCCTAAT CTCTACCAGT 1450 TGGCTCTTAG AGATCAGGCA GGAGGGGTGC CAAGAAGGAG AGTTCAAGGC 1500 AAGGGTGTTC ATTCCAAGGC CCCATCCCAA AAGTCCTCTA ACATGTAGTT 1550 GAGTCTGTTC TGTTGTGTTT GAAAAACAGT CAGGCTCCTA ATCAGTAGAG 1600 AGTTCATAGC CTACCAGAAC CAACATGCAT CCATTCTTGG CCTGTTATAC 1650 ATTAGTAGAA TGGAGGCTAT TTTTGTTACT TTTCAAATGT TTGTTTAACT 1700 AAACAGTGCT TTTTGCCATG CTTCTTGTTA ACTGCATAAA GAGGTAACTG 1750 TCACTTGTCA GATTAGGACT TGTTTTGTTA TTTGCAACAA ACTGGAAAAC 1800 ATTATTTTGT TTTTACTAAA ACATTGTGTA ACATTGCATT GGAGAAGGGA 1850 TTGTCATGGC AATGTGATAT CATACAGTGG TGAAACAACA GTGAAGTGGG 1900 AAAGTTTATA TTGTTAGTTT TGAAAATTTT ATGAGTGTGA TTGCTGTATA 1950 CTTTTTTCTT TTTTGTATAA TGCTAAGTGA AATAAAGTTG GATTTGATGA 2000 CTTTACTCAA ATTCATTAGA AAGTAAATCA TAAAACTCTA TTACTTTATT 2050 ATTTTCTTCA ATTATTAATT AAGCATTGGT TATCTGGAAG TTTCTCCAG 2099 (2) INFORMATION FOR SEQUENCE ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: Glu Ala Asp Pro Thr Gly His Ser Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: Glu Val Val Pro He Ser His Leu Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: Glu Val Val Arg He Gly His Leu Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: Glu Val Asp Pro He Gly His Leu Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: Gly Val Asp Pro Ala Ser Asn Thr Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: Glu Val Asp Pro Thr Ser Asn Thr Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Glu Ala Asp Pro Thr Ser Asn Thr Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: Glu Ala Asp Pro Thr Ser Asn Thr Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Glu Val Asp Pro He Gly His Val Tyr 5 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: single (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: Tyr Met Asn Gly Thr Met Ser Gin Val 5 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Met Leu Leu Ala Val Leu Tyr Cys Leu Leu 5 10 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: Met Leu Leu Ala Val Leu Tyr Cys Leu 5 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Leu Leu Ala Val Leu Tyr Cys Leu Leu 5 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: Ser Glu He Trp Arg Asp He Asp Phe Ala His Glu Ala 5 10 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: Ser Glu He Trp Arg Asp He Asp Phe Ala 5 10 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41 Ser Glu He Trp Arg Asp He Asp Phe 5 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gin Asp Leu 5 10 15 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu 5 10 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: Ser Ala Tyr Gly Glu Pro Arg Lys Leu 5 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1032 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: CGCCAATTTA GGGTCTCCGG TATCTCCCGC TGAGCTGCTC TGTTCCCGGC TTAGAGGACC 60 AGGAGAAGGG GGAGCTGGAG GCTGGAGCCT GTAACACCGT GGCTCGTCTC ACTCTGGATG 120 GTGGTGGCAA CAGAGATGGC AGCGCAGCTG GAGTGTTAGG AGGGCGGCCT GAGCGGTAGG 180 AGTGGGGCTG GAGCAGTAAG ATGGCGGCCA GAGCGGTTTT TCTGGCATTG TCTGCCCAGC 240 TGCTCCAAGC CAGGCTGATG AAGGAGGAGT CCCCTGTGGT GAGCTGGAGG TTGGAGCCTG 300 AAGACGGCAC AGCTCTGTGC TTCATCTTCT GAGGTTGTGG CAGCCACGGT GATGGAGACG 360 GCAGCTCAAC AGGAGCAATA GGAGGAGATG GAGTTTCACT GTGTCAGCCA GGATGGTCTC 420 GATCTCCTGA CCTCGTGATC CGCCCGCCTT GGCCTTCCAA AGTGCCGAGA TTACAGCGAT 480 GTGCATTTTG TAAGCACTTT GGAGCCACTA TCAAATGCTG TGAAGAGAAA TGTACCCAGA 540 TGTATCATTA TCCTTGTGCT GCAGGAGCCG GCTCCTTTCA GGATTTCAGT CACATCTTCC 600 TGCTTTGTCC AGAACACATT GACCAAGCTC CTGAAAGATG TAAGTTTACT ACGCATAGAC 660 TTTTAAACTT CAACCAATGT ATTTACTGAA AATAACAAAT GTTGTAAATT CCCTGAGTGT 720 TATTCTACTT GTATTAAAAG GTAATAATAC ATAATCATTA AAATCTGAGG GATCATTGCC 780 AGAGATTGTT GGGGAGGGAA ATGTTATCAA CGGTTTCATT GAAATTAAAT GTTATCAACG 840 GTTTCATTGA AATTAAATCC AAAAAGTTAT TTCCTCAGAA AAATCAAATA AAGTTTGCAT 900 GTTTTTTATT CTTAAAACAT TTTAAAAACC ACTGTAGAAT GATGTAAATA GGGACTGTGC 960 AGTATTTCTG ACATATACTA TAAAATTATT AAAAAGTCAA TCAGTATTCA ACATCTTTTA 1020 CACTAAAAAG CC 1032 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser Ala Gin Leu Leu Gin 5 10 15 Ala Arg Leu Met Lys Glu 20 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser Ala Gin Leu Leu Gin 5 10 15 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: Ala Ala Arg Ala Val Phe Leu Ala Leu 5 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: ATG CGA AGA GAA GAT GCT CAC TTC ATC TAT GGT TAC CCC AAG AAG GGG 48 Met Pro Arg Glu Asp Ala His Phe He Tyr Gly Tyr Pro Lys Lys Gly 5 10 15 GAC GGC CAC TCT TAC ACC ACG GCT GAA GAG GCC GCT GGG ATC GGC ATC 96 His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly He Gly He 20 25 30 CTG ACA GTG ATC CTG GGA GTC TTA CTG CTC ATC GGC TGT TGG TAT TGT 144 Leu Thr Val He Leu Gly Val Leu Leu leu He Gly Cys Trp Tyr Cys 35 40 45 AGA AGA CGA AAT GGA TAC AGA GCC TTG ATG GAT AAA AGT CTT CAT GTT 192 Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val 50 55 60 GGC ACT CAA TGT GCC TTA ACA AGA AGA TGC CCA CAA GAA GGG TTT GAT 240 Gly Thr Gin Cys Ala Leu Thr Arg Arg Cys Pro Gin Glu Gly Phe Asp 65 70 75 80 CAT CGG GAC AGC AAA GTG TCT CTT CAA GAG AAA AAC TGT GAA CCT GTG 288 His Arg Asp Ser Lys Val Ser Leu Gin Glu Lys Asn Cys Glu Pro Val 85 90 95 GTT CCC AAT GCT CCA CCT GCT TAT GAG AAA CTC TCT GCA GAA CAG TCA 336 Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gin Ser 100 105 110 CCA CCA CCT TAT TCA CCT 354 Pro Pro Pro Tyr Ser Pro 115 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 676 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: TCTTCATACA CGCGGCCAGC CAGCAGACAG AGGACTCTCA TTAAGGAAGG TGTCCTGTGC 60 CCTGACCCTA CAAGATGCCA AGAGAAGATG CTCACTTCAT CTATGGTTAC CCCAAGAAGG 120 GGCACGGCCA CTCTTACACC ACGGCTGAAC AGGCCGCTGG GATCGGCATC CTGACAGTGA 180 TCCTGGGAGT CTTACTGCTC ATCGGCTGTT GGTATTGTAG AAGACGAAAT GGATACAGAG 240 CCTTGATGGA TAAAAGTCTT CATGTTGGCA CTCAATGTGC CTTAACAAGA AGATGCCCAC 300 AAGAAGGGTT TGATCATCGG GACAGCAAAG TGTCTCTTCA AGAGAAAAAC TGTGAACCTG 360 TGGTTCCCAA TGCTGCAGGT GCTTATGAGA AACTCTCTGC AGAACAGTCA GGACCACCTT 420 ATTCACCTTA AGAGCCAGCG AGACACCTGA GACATGGCTG AAATTATTTC TCTCACACTT 480 TTGCTTGAAT TTAATACAGA CATCTAATGT TCTCCTTTGG AATCCTGTAG GAAAAATGCA 540 AGCCATCTCT AATAATAAGT CAGTGTTAAA ATTTTAGTAG GTCCGCTAGC AGTACTAATC 600 ATGTGAGGAA ATGATGAGAA ATATTAAATT GGGAAAACTC CATCAATAAA TGTTGCAAAT 660 GCATAGTAAA AAAAAA 66 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13585 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (D) OTHER INFORMATION: at positions 9421-9456, the "Ns" refer to an unsequenced portion of from 4.7 to 5.3 kilobases (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: CCGTCAGAAA TCTAAACCCG TGACTATCAT GGGACTCAAA ACCAGCCCAA AAAATAAGTC 60 AAAACGATTA AGAGCCAGAG AAGCAGTCTT CATACACGCG GCCAGCCAGC AGACAGAGGA 120 CTCTCATTAA GGAAGGTAAG AGCGTTGCCT TCTCGCCATA ATCATAGTCC TCTTCTCCCA 180 GAATAGGATT TGGGAAATTC TGGCTAAGTC CTCTGCCTAC CCTCATTGCC CCGCTGATGT 240 GTGACATCAA CAGAATTTCT CCGCAACGTT TGTCAGTCTC CAACCTCAGA GGGCTCACAA 300 AGCCTCCTCC TGAATCCTCT CTCAGTCCTC CAACACTACC AAGAAGAAAA GCAATTATTC 360 AGGATGGCAT CTTGCTGGGG AGAAGCAGCC TCCCTGAGGT AGATGTGTTC TCCTGTCACT 420 TAAAGAACCA CTTCTCCTGG TCTGAGTAGT AAGAGGCGCA TTTGCTGTTG CTGCACCATT 480 TGCCAAGGCT CTGAGTTTGA GGTATGGGAT GTATTAAAAC AATTTAATGA AGAATTAAGA 540 TTCCATTCTG TCATTTTGAA CACAGGGTTC AGTCCTATAT TATTCACTTG AGAGGACTGG 600 TGAGTTTGAC TTTCATTTCT TTTTTACAAC TGGGAAGGGC AAATTACACA TAAAATGTCC 660 CAGTGGAAAG GGGTCATGTG TCGAAATCCC CACTCTTCTG TCTCACCTCT CCCTGTTGTT 720 TTAAACTGGG GCTCATTAAT ATAATTCTAT GGGGATCACA CCTTTGAAAT TCATGAGGAC 780 AGTAAGAGAG CAGAAAAATA CACAATAATA AGGAAAGGAG CTTCCATTAT TGGTTTTTAA 840 TGAGCGTACT TGAATTACGG CCACTGCaGT TTATGGATAT TTTTTGTTGT TCATTTGTAT 900 GTGTTATAGT TAGAAAAAAA AAGAATCCTA GCCAAGGGAC TTGAACCAGA GAGAAGCAGA 960 AATTGACTTA AGTAGGAAGG GAAACACATT ATTAGATAAA GTCAGGTCCT GGGCTTCCTC 1020 GGCTTGTTTT GGGTGGAGTG CCTGGGGACA GGCTGAAGCC CCTGTGTGGG GTGGTTTCCT 1080 TTGCTGAAAA GCTGGGCTGG AAGATGTTGT GCTCAGTGCT CAACCTCATG CACCCTCGCG 1140 AGGCACAGGC AACGGGTGCT CTGGGAAACA CACGTTATGT ATCATAGCCT CTGTTTGTCT 1200 GTGGGATTGA TATCCAATAA TAACTTTGGA GAAAAATAAC TCCTCTTATT TTGTTAGCCA 1260 CAGCCCTGGG CCAGGGAAGG TGGAGAATCA GTGAAAATGC ATTTTGTTTG TTTCTCTAGA 1320 AGTTTATGGT GCAGAGTCAA ATTGAAGGCA AATGAGGAAT ATTTTTTCAT TAAATAATAA 1380 CTCAACTTGC AAGTCTTTTT TGCTTTTGTT TGTAGTTTCT TCTTTGAACT TAATTTTCAG 1440 TTAGTAGGAG GGGTTAGAAA CCTGAGCTAT TGCTAAAGCC CTTGATATGA ATGAAAGAAG 1500 CAGGTGCAAA TCCCCTCACA GAGAGAAACC AAAGGGTCCT GGCTATGGAT ATTGGTCACC 1560 TAGTCAGGAT GCTGTTGTGG GTCTTTATGA GATGATGAAT AGGGTGGCTT TGGATGCATT 1620 AATGATATTT ACATGCTCCT TCTGTTAGTG TCCTGTGCCC TGACCCTACA AGATGCCAAG 1680 AGAAGATGCT CACTTCATCT ATGGTTACCC CAAGAAGGGG CACGGCCACT CTTACACCAC 1740 GGCTGAAGAG TAAGTTCAAA ACCAGACCCA GCAGGGCTTC CAGTTTGCCG TTTGCTGACA 1800 CAGCCTGCTG ACTTCCACCA GTACATGCCT GCTCGTAAAT CTCCCTAGTG TTTATCTCCC 1860 CAGACAGTAA CATCCCTGGC AACAAGGGGA GGAGATTCTG TGCTTCTATA AGGGGCTCAG 1920 TCAAGCTTCT CTGAGGCCAA ACAGGCAGGA AGATGGGAAT GGTATAAGGT TGGATCTTGC 1980 CATTTTTGGG TGCACTTTTG ACTATTGGGT CTTATCTGTA GGTTCCCAAG TGGAAAAACA 2040 TCTGTTCAGG ATCACAATGC CTCTCTCCTC AATCCTTGTT CTGTCTCCTC CACTCAAATT 2100 CCTGAAGGTG GTTTGCAGAC AGAATAAAAG TGAGTTGCCA AGGAGCCAGT AAGGATGACG 2160 GGCAGGTGTG TGTGACTCAG CCCACAGCCA GACTCGAGAG GAAGATGGAG GTCACAGCCT 2220 TTGCAGTATA ACTTTATCCT AAGGAAAGAC ATTGGGTTTT ATGAGTGAAT TAAAAATAAG 2280 TATTTATATG ATTAAGCATT TCTAAATGCT AAGCATTGTA TACTGGCGTG AGACACTGTT 2340 TTTATCTTTG AAAAAACTCA CAACTTAGTG GGAGAGTTAG GCATGAGATT AATTTCAGCA 2400 AATGTAAGTG CGGTAATGAA AACCCAGAGG CTGCAGGGAC ATACTCTGTA TGTGCTGGGA 2460 GTGGGAAAGG GACATACTCT GTACGTGCTG GGTGGCAGGG GCAGGGGAGG CCCCACCCTC 2520 TGCGTGGGAC TGTAACAGGA CAACACCCTC TTATGTGGTC TGTCCAGAAC TCCCTGTGAA 2580 CCTGCTCTTT CTTTGGAAAG AGCTGTTGAA CAATCTTTGT TAACAGTCAA CCGCAGGACC 2640 AGCAAGATGT AAAGCCCAAC AAAGGCACTG AGGAAGAGTT CAGGAAGACA GCATTTCCTC 2700 AGAAGACCCT GGTATAGGAT CCTCTAATAT CCCTGGCCAA TTGGAGATGA GGGCGGCGGT 2760 ATCCTCTCAG AAAATGTCCT GACAGCAAAA ACATACTCTT TGAGGGAGGG GAGCCCATTG 2820 CCCGTGCTAT TAGTTAGGGT ATCGTTTCAG CTTGTGTATA ATCACTCAAC AGACTCTTTA 2880 AAATATACTT TTATGTCTCG TGTAAAAATT CAAGAGTAAA GAGTTCAAGG CCTGTTCGTT 2940 TTCTTCTTGC TGGTTACTCC CTTGGGATCG TCACTTTTGT CCCCATGGCT GAAGATGTTG 3000 TGCCATCACC TCCACATCTT GCCAACAGAA AGCAGGAGGT GAAGGAGAGG CTAGGACCAT 3060 TCCTTTCAAG GGGCACACGT CACTTCTGCT TATTGCTCCA CCCCCGCCCC CCGCCCCGTG 3120 GCACCCACCC TGGTGGTATC ATTCTTGCTG TGTTGTAAAT GAAGAAAGGT TTAGAGAAAT 3180 TAGGAAATGT GTGGCCAGAC ATGGTGGCGC TGGGATTTAA ATCCAGGTCT GTTTGCCTCC 3240 AGAGTCCATG CTCTTAAGTG TTATGCTGCA GGCCAGCAGA GGCAAATATT TGCACAATCC 3300 CATCCGACGA GAGGCTAGGG CAGAGGTCAG TATCTCTCAG TGTGAAGCTG GAGGCTGATG 3360 CTAGTCAGCT CAGTAGGCCG AAAGTGGAGT TGTCCTTTGC CATGTAGGGC CATCATGCCC 3420 AGCTGGGGAA CCTCATAGCC AGGTGTACCC ACAACCTGAA CAAGGTAACT TTCAGGGTCT 3480 AGTCAGGAAG AAACCAACTA GATGGTTCAA CATAGAGACT TTAATATAAG AAGCTGGTTA 3540 AACAGGCATG GGACTGAGAC TGAGGAGGCA AAGAAGGCAT CGGGGCAACC AAGGCTGTAC 3600 CCACAGAATG CTGCTTCTAC CCCCGTGTCT GGGGTAACAA ACGGAAGGGT GAGGCCATCA 3660 GGACCTAGAG TTGGGAGGAG GGACGCCACA GAAATGGGAC CCAGATCTCT AAGGAGAGAT 3720 TTTTGTTTGG CTGGTTCTGG TGTCTCAAGA GCTTAGAAGT GAGGGGCATG AATCAAATAC 3780 TCAGGCCTCT GAGGTCAGCC AGTGCTCTGC TGGGGAGGGG CATAATGAAG CTGGCTCTGA 3840 CAATGCCGGA AAACGAGCTG GTGCTTGGCA TATACAGACA ATGTGAGCAT TGCTGGGGTG 3900 ATCCTGACAG GAGCCAGAAG CACACTGGAA GGAGCTGCTC CTTCTTGATG CCCCAGGTTT 3960 GTAGGCACCC TCTAGAGTAC TCTAATGGGA GCCAGTGGGC AAAGGAGAAG TGGCATTTGC 4020 AGAGTCCAGT CCCAGCATCA CAGAGCAGAG CATAGAAAGG TAGGTTTGGA GAAGAGGGAC 4080 AATGGCTTAA TAAAGGGCAA AGGGGGTTAT GACCACTATC ATGTGAAGGA ACCCCTTGAC 4140 TGAAGGCACA AGCTTTCTGT GTCTTGCAAC CTGAATGACG TGCATAAGCA GGGTCAGGTG 4200 GGTTATCTGA CATTTTCCTT GAGAACAAGA GGGAGCCTCT GGATTCCAGC ACAAAAGAAA 4260 AATACCCACT CAACCCGTAT GCGTGGGAGC TATCCTTTAA AGAGAAAGTA ATTCCTTTTG 4320 ACATTTTGCT GTCTGTAGAA GGGTCAGATG GCCAAAGCTT CCAGCACAAT GAAACACTTA 4380 ACTTCAGTCT GTGAGTGTAG GAACCCCTGA ATACATGGAA CATCATCATC TTGTGCAGGT 4440 ACTGAAGGAG ATCGGTCCAG AAAATAAGTA ACTGCACATG GCCACCAATG TCAAAAGTCA 4500 TTCCTCTCAT GAAAAGTCCC TGCCCCCATT GCTGTTTGTT TAAATAGGTG GGATGGAGGT 4560 AGGGGAATGG GGCCATCTTC TTTTTTTTTT TTTAATTTTT TTGCATAAAA TCCAGATCCT 4620 GCACAATGGG GCAATCTTCA TTAAAACAAT GCATCCCTAA GATCTGAGAA TATTTATCCT 4680 TCTCACAATT GTGCCAGCAG GTGGAATGAA GAAGAATGAT GCAAAATAAG TTCCCACATC 4740 CAGCCAAGAA GGACTACATA CCTGCTTTGG GTATTATGTA TCCCTTTGAA ACCTCAGTGG 4800 AGAGCAGTTC TCACAGTTGG GTGGACACAA GTCATCCATG GAACTTGTTA AAATGCAGAT 4860 TTCTAGGTGC TGCCACCTAA GAGGCTGATT GGGTAGGCCA GGGGTGGAGT CCTATGATCT 4920 GCACCTTAAC GTGCATCTCA GGTGATTCTG CTGCAGGTGG TATTTGGAAG ACACTCTGAG 4980 GCGCCCTGCC AAGCTGGGCA GTGGGTTCTT CCAATGTGTC AGGCATACCC TGGTGCTTTT 5040 CGCTCTCAGT CACTTGGGCA TGTTGTGAGT ACCACGTGAC CATGCATAAA GTGCTGTAAC 5100 AGAGCTCTGT CTGTGTCAAG ATATTCAAGT GGACGCCACA GGGTAAAATG AGAGCACAGG 5160 CATGTTGGGA GTTGAATCAG CTGCCTTCAG TCACGAGAAC ACACTGAACA CTCCTTGTGA 5220 CAGCTTCAGT TCAGGAAAGA GTGACTCTGC AGGAAAAGCA CTGGCCTGGG AGACCTGGAT 5280 CTGGCCCAAA TTCTGGTGCT CACTTGCTTG GTCTCCCGTT CCAGTTGCTG TGAATGTTGG 5340 TTCTGCCACT TGCTGGTTGT GCAGCCCTGG GCACTTGACC AGCATAATGT CAGCTGTAAA 5400 ATGAACATCA TTCCTAACTC CGAGGACTGT GGTTAGGATG AAATAAAAGC ATATATGTGG 5460 GGGTGCCTAG CCCAGTGCCT GGCACAAATT GGTGCTCAAT GAATGGTAGT CACTATGGTT 5520 ATGGTAATGT TGATGAATCT TCATAGGTCT CAGCTTCCTG ATCTATAAAG CGGGTGGACT 5580 GACCTACATA AGTCAGAGTT TCCATCTAGC ACTGTCATCC CATGGTTCGC TCTATCCTGT 5640 TTGGAGACGG ACAGGATAAG CTTGATGTCT CCTCAGCCTT GAGACAGAAG TTGTCCAGTA 5700 GATGGTACTG AGCAAAAGTC TCTCCAGCAG AAGCCTTAGT TAAACCTTGC TTCTCCTGTA 5760 GCTGCTCAGT CTCTTGTAAG TCACTCAGCT CTGCAGAAAC TTTCTTAGCG AGTTGACAAC 5820 CACAGATAAC AGAGTCAGTT CTGTCGATTT TGATCATGCT GTGATCAGGC AGATGTTAGC 5880 TAATTGATGA TGCTTGCCCG GAGTGAACAG CTCCAGGCCC TGTTTCCAGG GTCTTTGTGG 5940 TAACTTTGTG GTAACTGTAA TGCTTCCCAG GGGTCACTGA ACACAGGGCC CAAGAGGCTG 6000 GTGTAGACCC CCAGATTGGC ACCCTGCTGC TTAGACAAGA TCCTTCTCAA TAAGTAATGC 6060 CATAGCTTTG CTGTAGGTTC AGCCCAGACA CTTCTCCCTA GGGCTGCAAG GAGCAAAGCG 6120 GGGAGTTTAG GGAAGGGAGG GCACGAACAT AATTGAGACG GATTCAGGTT CAAATCCAGC 6180 CTCTGTTTTG TGCTAGCTCT GTATGATCAC CAGCGAGTCA TGTATCCTCT GCCTTTTATT 6240 TCCTCTTCTG TGAAAATAGG GGATGATAAA TTGTGTCTAC CCTCCAGTGT TGATGTGAGA 6300 ATTGAATAAG CTAATGAATG TTTAGCACAG CACCTGGCTT TTAGTAGATG AGTCAGTGTT 6360 AATTTCTATT TTCTCTTTGT GGGCTGAGTT GGAGAAAATG TTTTAAAACA GCCTGATGAG 6420 AAGAAAAGAT AATTTAGCCC CAATAAATAC ATTGTCCACA TAAAGACAGT TACTATGGCA 6480 CTTCTCATAC CTGGAACTTG GGTGCCTGGG CCATGCAATT AGCAGAGTTC CTGTGGGCAC 6540 ACACTTGAGA GGCTCCTAAA GACCTGGGTT AGATCCAGGT GCTGGAGGCC TGGTGGGGTG 6600 CCAGTGTGGG AGGTGGGAAA CTACTTGGAC ACTGGGAGAT GCTGCTCTGG GTCGTCAAAG 6660 TCCATATGAA GAGGAAGACT GATTTATGCT TCATCATAAT GTAGAACAAT GTTTCAATGA 6720 CAAAGTGGAT TTGTCTATCT CTTGGGCCAG GCCGCTGGGA TCGGCATCCT GACAGTGATC 6780 CTGGGAGTCT TACTGCTCAT CGGCTGTTGG TATTGTAGAA GACGAAATGG ATACAGAGCC 6840 TTGATGGTTG GTAAAGTTCC CACTGCTGAA ATCCCTCCAA GTCCAGGGCC CTCTTTCCAG 6900 TTCTTTCCTC TGAATCTCTG GAGAGTCAGA TAATTGCCTC ATTATAACCT TCAGCTCTGA 6960 TTCCGGCTTC TGATGCCTCT TTTGCTACAT TGTACTTTGG CAACTCTACC TTTGCCTCTG 7020 CTCAGGCATG AACCTCAACC AGGAACTTGC CCTGTGTCTT AGTCTGTGAT TATAACATAA 7080 TACGAGAGAC TGTAATTTAT AAATAAATGA AATTCATTTG GTTTACAGTT GGGAGGCTGG 7140 GAACTCCAAG ATCTAGGGGC CACACCTGGT GAGGACTTCT TGCTGTGTCA TATCATAGTG 7200 GAAGGCATCA CATGGGCAAG GGAGTGAGAG AGCAAGAGGG AGCTGAACTC ATTTTTTTTT 7260 TTTCTTGAAA CAGGAAATCC TGGGATGGAG CGCAGTGGTG ATCATGAGTC ACTGTAGCCT 7320 TGACCTCCTG GGCTCAAGCC ATCCTCCTGT CTCAGCCTCC AGAGTAGCTG GGACCACAGG 7380 CACGTGCCAC CACACCGGCT AATTAAAAAA AAACTTTTTT TTGTAGAGAC GAGGTCCCAC 7440 TATGTTGCCC TAGGCTGGTC TCAAACTCCT GGGCTAAAGT GATCCTGCCT CGGCCTCCCA 7500 AAGTGTTGGG ACTACAAGTG TGAAACACTC CACATATGGC CCAAACTCAC TTTTATAACC 7560 AACCTACTTT TGCAATAACA AACACACTCC TGCAATAACA CAATTAATCC ATTCGATGAG 7620 GACAGAGCCC TTGTAACTTA ATCGACCTCT TAAAAGTCCT GCCTGTTACC ATTGTTGCAT 7680 TGGGGATTAG GTTTCCAATA CACGAATTTT GGGGGACACA TTCAAACTAT AGCACCTGTC 7740 TCTTTGGTTC TACTCATAGC AGACTTGGGT ACCTGGATGT TGTGTGTAGC TAAGCACTGA 7800 CGGTTTATAG GGCACAGGGG AAGGGGTTTG AGGTTCCCTT ATAGCAAACA GGAGTATATT 7860 AGACACCTCA GGTTTTACCA CTTCTGGGAA TTCTTGCTGG TTCTGTTACT CCACTTTGTG 7920 ACCTGCTCTT CCTACTTTTC TTCTTCACCC CTTTCCTCAC TGGTTACCTG TGAATTCCAA 7980 GTTCTTCTGA CTCTACACTA AGCATCCCAG GATATCATCA GTGCGATGAG GAAACCATCC 8040 TTCCTGCATC AGCACAAAGG GTCACTTGTG TGTTTTTTAA CAGGCTGCAT CCTTCTTAGA 8100 TGGCCAAAGG TTTTAATAGT ATTTTTTTCT TCTTTACCCA AATATGCAGG AAGCTAACAC 8160 AATTACACAA TCCAATCTTC TGGTACCAGT ATCCTCCATG AATGGGAAAC ATCAACTGAG 8220 TTTATAAGCT ATAAAAATTA CAGGTTTCAG CAATCTTGCT TAAAGCCAGG TAGCACTTCA 8280 GCACTTCAGC ACCCGAAGCA TTCTCCATAG ATCTCGCTGT CTCTCTTTCT TGTTATTACA 8340 GATCTGAAAG CTTTTCAGGT TGATGCATAA TGGAAAAAAA GTATCTTTCC AAAAGATGTT 8400 GGAAAGTCCC ATTCTCATTC AGCAAGCACT TCATTTAGAG GAAAAGGTCC TGTGAAAGAG 8460 AGGAGGGTTG GTGTGGGGTG GGGATTGAAG CTTGGCAAGC TGATAAGGAG AAGGTGAGAG 8520 ATACAACTCT GGATTCTTTC CCTCTTTGCC AAGAAACTTG GGCAGTCTCA TGTCTCATGT 8580 CTCCTGTTCC CCAATGTCTT TCCAGAGCAT AAATACAAAT ACAAACCATC AAAGGCAAGT 8640 CAAGTCTGGG GGCTGACACA CCCACCGAGC ATAGCCCTCT AGTGTGCTGA CATCTAGTGG 8700 GAAGGAGGAG GAGTTGATGA ATCTGAACAA GACTCCAATA TTGGAGGAAA TACTTGAGGA 8760 AAGCCTTGGG TTAGAAAGTT AGGGATAGAA TTCCTGCTCA TACGGCTGTC CACAACAGGT 8820 TAGTAGGGGA GGACTTTAAT CTCTGCCATA GAACTCCATT TGTAACTCTA GCATGGGGTT 8880 ATGACATTGC CTTGTAATTG GCTATTTACT TTTTGCCTCT TCGACCCCTC CGCTTTCCCC 8940 TATGTATGAA CCACAACAGA GAATATTTCT AACTCATCTT CATATCTCCA GTGCCTAGCA 9000 CAGTGCCTGG TACATGGTAG TCACTCAATT GTGTTGCATT AGGACTTGGT CCCATTGTCT 9060 GCCATTGAGT TGCTTGGAGA CTAGAATTCA ACTTCTCCAA GATTCACTAG CTCTATTTTA 9120 CACCCAGACA TGTTGGAAAT CTGTGATGTA ACACAATGTA TATCCATTTT TATTTAATAC 9180 ATATTTTCTT CTATATTTTG ATTTCATTAT ATATTTGTAT ATCAAAAACA AAATGTTTAG 9240 TCTTTCAAGA AGTAAAGCTA TACAAACTCA ATATGTTGGT ACTCATTTCC TAACTATAAT 9300 TATTAGTTTG ATCCTATTGA ACACAAATGC AGTAATTTTT CTTTTCTGCT TCAATGCTCT 9360 CATCTTAAAT TCATTTAATT GAAAAATAAC AGAGAGTCTT AATGTCATGT GCTCAGACAC 9420 TNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNGAGT GCAGTGGTAT GATCTGGGCT 9480 CACTGCAAGC TCTGCCTCCT GGGTTCATGC CATTCTCCTG ACTCAGCCTC CCAAGTAGCT 9540 GGGACTACAG GTGCCCGCTA CCATGCCTGG CTAATTTTTT GTATTTATAG TAGAGATGTC 9600 ATTTCACTGT GTTAGCCAGG ATGGTCTCAA TCTCCTGACC TCGTGATCCA CACGCCTTGA 9660 CCTCCCAAAG TGCTGCGATT ACAGGTGTGA GCCACCGTGC CCGGCCTTAT ACTTCTTTTT 9720 TACTTTTTTT CAGTGGTTTC CCTAGAGTTT GCAACATACA TTTACAACTA ATTCAAATCC 9780 ACTTTCAAAT AACACTATAC CATTTCATAG GCATTATGAG TATCTTAAAA TAATCCTAAT 9840 TCCTTCCTCC TGTAAACTAA AAACAAAATC CTAAATCCTC CAAACAACTG AATGGACCCC 9900 CTCTTCACCA AGGGGACCCC AGGGAAACCT GAAAAACTGA GTGTTGGCCA TGACGGGAAG 9960 GGAGGTGAGA GATGCTCATT ATACTCCCTC CCTTTTAGAG TTTTAGGTAC AACTGACCAG 10020 CATTAATTTT AAAATAGAGA TTACAGGACT GACAGAATGA ACTCTTTGTG GCAATATCAA 10080 ATTAGGAACA AGACAATGCA AGGAAAGGGT TAAATCATGC CCTTCAAACC ATAAAAAAAT 10140 TTTTTTTTAA TTAACCCCAT ATAATGTGGT ATACTTTCCA AACTGACTCT GGTATAGCAT 10200 CACATGACAG ATTGCAGACT CCCTTACCTT AAGCATTCCT TTATACTGAC TTCAAGTCTT 10260 AAGACAGAGC TGAACTCTTT CAACCAGCTG CTAACTAAAG AATACCTAAA ACCCACCTGT 10320 GACTTGTAAG TCTCTGCTTT GCCATGTCCT GCCTTTTCAG GCTGACCCAA TGTATACCTT 10380 CCGTGTATTG ATTTATGATT TTTACCTACA ATTCCTGTCT TCCTGAAACA TATAAAACCA 10440 AATCATAACC CAACCACCTC AGGCACACTT TCTCAGGACC TCTTGAGACT ATTCTCCCGG 10500 CCATGGTCAT TCATATCGGC ACAGAATGAA ACCTCTTTAA AATATTTTGC AGTTTTTTTC 10560 TTTCTGTTAA CATTCCTTTC CCTTGTATCA TTGCTGTTAT TAATTTCAAG TATATATAAG 10620 CATACCTAAT TAAATACATT GTTGCTATTA TTCATTTTTG AACAAACTAT TATCTGTTAA 10680 ATCAACTAAG AATAAGACAA ATATGTTGGG TGCAGTGGTG CATGCCTATA GTCTCAGCTA 10740 CTCAGAGGCT GAGGCAGGAG GATTGCTTGA GCTCAGGAGT TTAAGACCAG CCTAGGCAAC 10800 TTAGCAAGAT CATGTCTCTT AAAAAAAAAA AAAGAAAGAA AGAAAAACAA AGTTTTAGGA 10860 GGCTGAGGCA GGAGTATCAC TTGAACCCAG GACGCAGAGG TTGCAGTGAG CCGAGATCGT 10920 GCCATTATAC TCCAGCCTGG GCAACAGAGT GAGACTCTGT CTCAAAAAAA AAAAAGAAAA 10980 GAAAAGAAAA GAAAAAAAAA GTTTTTATTT TACCTTCACT TATTCCTTCT TGGATGTTCT 11040 TCCTTTATGT AGGTACAAGG TTCTGACCTA TGTTATTTTC TTTTTCTCTA AAGAACTTCA 11100 AAAGTTTCCT GCAAGGCAGG TCTACTGGCA ATGAATTCCC TCAATTTTTG CTTGACAAAG 11160 TCTTTATTTC TGCTTCACTA TTGATGGATA ATTTCACAAG AGTGTTCCTT TTGTAGATTC 11220 ACTCTTCTTA TCCTTCCCTT CAGAAATATT CTTTGACCAA CTATTGGGTC CCAGGTACTG 11280 CACTAGAGCT TTACTTCTAG TTAATTCCCA CAGCAATTCT GAGAGGTAGG TAGGTATTAT 11340 ATTCCTAGAT GCAAACTCAG AATTCAGAAG GTAAAGTGAT GAGACTGAAG GCACACAGCA 11400 AGTAAGTGGC AGAACCTAGA TTAAAACTCA TTCTTAAAAC TTTGGCTTCC TTCTCTTTTC 11460 TTTAATGGAT TCAGTTACTT CTTCTCACCC ACTCACCTTT ATCAATTTAC ATTTCAGATA 11520 AAAGTCTTCA TGTTGGCANC TCAATGTGCC TTAACAAGAA GATGCCCACA AGAAGGGTTT 11580 GATCATCGGG ACAGCAAAGT GTCTCTTCAA GAGAAAAACT GTGAACCTGT GGTAGGTTAA 11640 GATCCTTCAT AAGGGTATTT TCATGAATGG CTGTTTTTAA CTCAAGTGAA TACAATTATT 11700 TCCATTTAAA AAGCAAGGAC AATGTGAATG TACTCATTGC CACTGAACTA TATACACCTA 11760 AAAATGGTTA AAATGGCAAC TTTTATGTGT ATTTTATGAG AATAAAAAAT AAATAATAAT 11820 AAAAAACAAG GGAAGTACAG ATATTTTCTT AATTGTGTTG TCACATACCC AGTGTTTCCA 11880 GGGTCAATAA TGAGAGCCCT ACATGTAAGA TTCAAAGGAA GAATTTAGTC CTGGATACAA 11940 TATTCTTTTA TGTTTTTAGT TATATTTGCC TTTTTAATGG ATGCAGATAT ATACAGAGGG 12000 AAGGGATAAA GTACCTATTA TTTATTGTAT AGAGCTGTGC TGTCTGATGG CTTAGCCACT 12060 AGTCACATGG TGCTATTGAA CACTTAAAAC ACAGGAGTTT GAAATAAGCA TGTATTATAA 12120 TACATATCAT ATTTCAAAAA TATTAGTATG TAGAAAAGAA GATAAATGGT TCATTAATGA 12180 TTTTTATATT GATTCACCTT GAAATAAATA TTCTGAAAAT ATTAGGTTAA ACAAAATATT 12240 TTAAGATTAA TTTTACATGT TTCTTCTTTT AAATGTAGCT ACTAGAAATT TTAAAATTAC 12300 ATATGGCTGG GCATGGTGGC TCACACCTGT AATCCCAGCA CTTCGGGAGG CCGAGGTGGG 12360 TGGATCACCT GATCTCAGGA GCTCGAGACC AGCCTGGCAA ACATGGTGAA ATCCTATCTT 12420 TACTAAAAAT ACAAAAATTA GCCAAGCGTG GTGGTGCATG CCTGTAATCC CAGCTACTTG 12480 GGACGCTGAG GCAGGAGAAT CACTTGAACC CGGGAGGTGG AGGTTGCAGT GAGCCGAGAT 12540 AGTGCCACTG CACTCCAGCC TGGGAGACAA GAGCAAAACT CCATCTCAAA AATAAATAAA 12600 TAAAATAAAA TTACATAAGT GGCTTGTACC ATATTTCTAT TGGACAGCAC TAGTACATAT 12660 ACAACACAGC ATAATGGTTG AGAGCACTGA CTCTGGAGCC AAATTACTGT GTTTGATTCT 12720 TAGCTCCACA ACTTACTAGT TGTGTGACCA TGGGCAAGCG AGTTAACCTC TCTGTGCCCC 12780 AGTTTCCCAT TCTGTAACAT GAAAATAATA AAAACACTCC CCAGAATTGT TGTGAGCATT 12840 AAATGAAGCC CTGACACATT TGTTCTGGAT ACAATATCCT CTTGTTTTAT ATTTGGTAGT 12900 ATCAATGTGC CTTTAGACAC AATTACAACG ATCTCTGTGG TAAAGATGCA ATGTATATGG 12960 TGTCTATAAA TAGCATTCAA TGATTCGTTA GTTAGGGCTT GAGACTTTTA CTGTCATGGA 13020 AAATCTAGGT ATAGCTAAGC TTTTGAGATT TTGGGAACTC CTTAACCCTA TTTTTCTCTA 13080 CTCTTGCCCC CAACAATCAG CCTATATACT TGTGAAATTT AACAATTACT TCACTGGGCA 13140 GAAATTATAT GGGAACACTT AGAAATTTCA GTCCACAGGG AAAGTATAAA TATGTTAACT 13200 ATTTTAACTT AATCCCTTCC TAGAAACACA TACACTGTTG CCAAGCCCAT ATTCTCCCTT 13260 TCTTGTTCTC ACAGTTCCCA ATGCTCCACC TGCTTATGAG AAACTCTCTG CAGAACAGTC 13320 ACCACCACCT TATTCACCTT AAGAGCCAGC GAGACACCTG AGACATGCTG AAATTATTTC 13380 TCTCACACTT TTGCTTGAAT TTAATACAGA CATCTAATGT TCTCCTTTGG AATGGTGTAG 13440 GAAAAATGCA AGCCATCTCT AATAATAAGT CAGTGTTAAA ATTTTAGTAG GTCCGCTAGC 13500 AGTACTAATC ATGTGAGGAA ATGATGAGAA ATATTAAATT GGGAAAACTC CATCAATAAA 13560 TGTTGCAATG CATGATAAAA AAAAA 13585 (2) INFORMATION FOR SEQUENCE ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 648 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: AGCTGCCGTC CGGACTCTTT TTCCTCTACT GAGATTCATC TGTGTGAAAT ATGAGTTGGC 60 GAGGAAGATC GACCTATCGG CCTAGACCAA GACGCTACGT AGAGCCTCCT GAAATGATTG 120 GGCCTATGCG GCCCGAGCAG TTCAGTGATG AAGTGGAACC AGCAACACCT GAAGAAGGGG 180 AACCAGCAAC TCAACGTCAG GATCCTGCAG CTGCTCAGGA GGGAGAGGAT GAGGGAGCAT 240 CTGCAGGTCA AGGGCCGAAG CCTGAAGCTG ATAGCCAGGA ACAGGGTCAC CCACAGACTG 300 CTGCAGGTCA AGGGCCGAAG CCTGAAGCTG ATAGCCAGGA ACAGGGTCAC CCACAGACTG 300 GGTGTGAGTG TGAAGATGGT CCTGATGGGC AGGAGATGGA CCCGCCAAAT CCAGAGGAGG 360 TGAAAACGCC TGAAGAAGAG ATGAGGTCTC ACTATGTTGC CCAGACTGGG ATTCTCTGGC 420 TTTTAATGAA CAATTGCTTC TTAAATCTTT CCCCACGGAA ACCTTGAGTG ACTGAAATAT 480 CAAATGGCGA GAGACCGTTT AGTTCCTATC ATCTGTGGCA TGTGAAGGGC AATCACAGTG 540 TTAAAAGAAG ACATGCTGAA ATGTTGCAGG CTGCTCCTAT GTTGGAAAAT TCTTCATTGA 600 AGTTCTCCCA ATAAAGCTTT ACAGCCTTCT GCAAAGAAAA AAAAAAAA 648 (2) INFORMATION FOR SEQUENCE ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: Ala Leu Ser Arg Lys Val Ala Glu Leu 5 (2) INFORMATION FOR SEQUENCE ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: Phe Leu Trp Gly Pro Arg Ala Leu Val 5 (2) INFORMATION FOR SEQUENCE ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: Thr Leu Val Glu Val Thr Leu Gly Glu Val 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: Ala Leu Ser Arg Lys Val Ala Glu Leu Val 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57 Ala Leu Val Glu Thr Ser Tyr Val Lys Val 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: Ser Thr Leu Val Glu Val Thr Leu Gly Glu Val 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: Leu Val Glu Val Thr Leu Gly Glu Val 1 5 (2) INFORMATION FOR SEQUENCE ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: Lys Met Val Glu Leu Val His Phe Leu 1 5 (2) INFORMATION FOR SEQUENCE ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: Val He Phe Ser Lys Ala Ser Glu Tyr Leu 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: Tyr Leu Gin Leu Val Phe Gly He Glu Val 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: Gin Leu Val Phe Gly He Glu Val Val 1 5 (2) INFORMATION FOR SEQUENCE ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: in Leu Val Phe Gly He Glu Val Val Glu Val 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: He He Val Leu Ala He He Ala He 1 5 (2) INFORMATION FOR SEQUENCE ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: Lys He Trp Glu Glu Leu Ser Met Leu Glu Val 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: Ala Leu He Glu Thr Ser Tyr Val Lys Val 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: Leu He Glu Thr Ser Tyr Val Lys Val Leu 1 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: M3-195.203 OR SEQ ID NO: 69: He Met Pro Lys Ala Gly Leu Leu He 5 (2) INFORMATION FOR SEQUENCE ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: M3-220.228 OR SEQ ID NO: 70: Lys He Trp Glu Glu Leu Ser Val Leu 5 (2) INFORMATION FOR SEQUENCE ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: He Asn Phe Thr Arg Gin Arg Gin Pro Ser Glu Gly Ser Ser 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: Leu Phe Arg Ala Val He Thr Lys Lys Val Ala Asp 5 10 (2) INFORMATION FOR SEQUENCE ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr 5 10 (2) INFORMATION FOR SEQ ID NO: 74 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1896 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74 GCGGCGGTGG CGGAGGCGGA CACATTGGCG TGAGACCTGG GAGTACGTTG TGCCAAATCA 60 TTGCCACTTG CCACATGAGT GTAAATGATG GCGGATGCAA GTATGTCCTC TGCCGATGGG 120 AAAAGCGATT ATGGCCTGCG AAGGTGACAG CCATTATTCT GTAACTTCAG GACTTAGAAA 180 TGACTTTCGG GTGACAAGTA AAATCTTGAT CAGGAGATAC CTAGGATTTG CTTCAGTGAA 240 ATAATTGAGC CAGAACACGG TTGGCACTGA TTCTCGTTCC CCATTTAATG GGGTTTTGGT 300 CTAGTGCTTC CAAGGTTACA CTTCCAGAAA TGTCTTTTTT TTTTCACACT AAAAAAAAAA 360 AAAAGAATCA GCTGTAAAAA GGCATGTAAG GCTGTAACTC AAGGAAAGAT CTGGCAAGCA 420 GCCCTGTGAT AGTAAATTAT GGTCGTGTTC AGGGAATGCT TTCCAGCAAT TCAGTAGACA 480 GTGCTCAGCT GCAATGCAAA AGCCCAGGTC CTTGTCTTTG TCTGCCACTG GCCTCTCATG 540 CCTCAGTTTC CCCATCTGTG AAACAATGGG GATTGGACCA AATATCTGAA ATCCCATGGT 600 TATAGGCCTT CAGGATTACC TGCTGCATTT GTGCTAAAGT TTGCCACTGT TTCTCACTGT 660 CAGCTGTTGT AATAACAAGG ATTTTCTTTT GTTTTAAATG TAGGTTTTGG CCCGAACCGC 720 GACTTCAACA AAAAATAAGA GAAGAAAGGA ATATTTTCTA GCTGTGCAAA TCCTCTCCCT 780 AGAGGAAAAG TTAATTGTTG TGTTGTTTTA ATACTGTTTT TTCCCGTGTA GATTTCTGAT 840 ACTTCAATCC CCTACTCCCC CAAAACAGTT GAAGCCCAGC CCACTCTTAA TGGGCTTATT 900 CACCATTTGT GTAATTCATT AATGCTCATA ATAACCTCAT GAGAAAGCAA CTAGTTTGAT 960 TTTATGTCAG TTTGGAAGCT GAAGATCCAA ACGAGGCATT CTGTGAGATC TATGGAGAGA 1020 TTGGTACAAA CACTGAATAC ATGTAAATTA TACTCAGGGT AGACCCTATT TGTGGTTAAA 1080 ATAGGGATAT TTCCTTTTTT TTTTTTTTTT TTTTGACTGT TTCTTAATCA GTGCCATGCC 1140 AGGAAAATAG GGATGTTTCC TTCCCAGAGA TCTGTGTGTC TTTTTTCAGA AACGTCTGTG 1200 ACAGGCCCAT CAATTTTGAA ATATTTGGTT TTTGAGCCTG TCACTCTAAA CCAGCGTTTA 1260 ACGTTCAAAA GGCAAATAAC TGATGACCAG GCGGCACATT GTTCTGCTCC GTGAGTGTCT 1320 GGCACTGGGA AAGGTGTAGA TTGTCTAGAA TGACAGCAAT TCCGACGCCC CAGTCAGTCC 1380 TGCGTGATTG TGGCGAGGGC GCGTCTGGCA CCGGGAAGGT GTAGATCATC TAGAATGACG 1440 GCGATTCCGA CGCCCCGGTC AGTCCTGCGT GATTGGCGAG GGTGCATCTG TCGTGAGAAT 1500 TCCCAGTTCT GAAGAGAGCA AGGAGACTGA TCCCGCGTAG TCCAAGGCAT TGGCTCCCCT 1560 GTTGCTCTTC CTTGTGGAGC TCCCCCTGCC CCACTCCCTC CTGCCTGCAT CTTCAGAGCT 1620 GCCTCTGAAG CTCGCTTGGT CCCTAGCTCA CACTTTCCCT GCGGCTGGGA AGGTAATTGA 1680 ATACTCGAGT TTAAAAGGAA AGCACATCCT TTTAAACCAA AACACACCTG CTGGGCTGTA 1740 AACAGCTTTT AGTGACATTA CCATCTACTC TGAAAATCTA ACAAAGGAGT GATTTGTGCA 1800 GTTGAAAGTA GGATTTGCTT CATAAAAGTC ACAATTTGAA TTCATTTTTG CTTTTAAATC 1860 CAGCCAACCT TTTCTGTCTT AAAAGGAAAA AAAAAA 1896 (2) INFORMATION FOR SEQUENCE ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acid residues (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: Glu Glu Lys Leu He Val Val Leu Phe 5 (2) INFORMATION FOR SEQUENCE ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1554 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : s ingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: DAGE (D) OTHER INFORMATION: Xaa is Arg when V is C or A or Gly when V is G (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: VGA CTG AGA CCT AGA AAT CCA AGC GTT GGA GGT CCT GAG GCC AGC CTA 48 Xaa Leu Arg Pro Arg Asn Pro Ser Val Gly Gly Pro Glu Ala Ser Leu 1 5 10 15 AGT TTC CGC AAA ATG GAA CGA AGG CGT TTG CGG GGT TCC ATT CAG AGC 96 Ser Arg Phe Lys Met Glu Arg Arg Arg Leu Arg Gly Ser He Gin Ser 20 25 30 CGA TAC ATC AGC ATG AGT GTG TGG ACA AGC CCA CGG AGA CTT GTG GAG 144 Arg Tyr He Ser Met Ser Val Trp Thr Ser Pro Arg Arg Leu Val Glu 35 40 45 CTG GCA GGG CAG AGC CTG CTG AAG GAT GAG GCC CTG GCC ATT GCC GCC 192 Leu Ala Gly Gin Ser Leu Leu Lys Asp Glu Ala Leu Ala He Ala Ala 50 55 60 CTG GAG TTG CTG CCC AGG GAG CTC TTC CCG CCA CTC TTC ATG GCA GCC 240 Leu Glu Leu Leu Pro Arg Glu Leu Phe Pro Pro Leu Phe Met Ala Ala 65 70 75 80 TTT GAC GGG AGA CAC AGC CAG ACC CTG AAG GCA ATG GTG CAG GCC TGG 288 Phe Asp Gly Arg His Ser Gin Thr Leu Lys Ala Met Val Gin Ala Trp 85 90 95 CCC TTC ACC TGC CTC CCT CTG GGA GTG CTG ATG AAG GGA CAA CAT CTT 336 Pro Phe Thr Cys Leu Pro Leu Gly Val Leu Met Lys Gly Gin His Leu 100 105 110 CAC CTG GAG ACC TTC AAA GCT GTG CTT GAT GGA CTT GAT GTG CTC CTT 384 His Leu Glu Thr Phe Lys Ala Val Leu Asp Gly Leu Asp Val Leu Leu 115 120 125 GCC CAG GAG GTT CGC CCC AGG AGG TGG AAA CTT CAA GTG CTG GAT TTA 432 Ala Gin Glu Val Arg Pro Arg Arg Trp Lys Leu Gin Val Leu Asp Leu 130 135 140 CGG AAG AAC TCT CAT CAG GAC TTC TGG ACT GTA TGG TCT GGA AAC AGG 480 Arg Lys Asn Ser His Gin Asp Phe Trp Thr Val Trp Ser Gly Asn Arg 145 150 155 160 GCC AGT CTG TAC TCA TTT CCA GAG CCA GAA GCA GCT CAG CCC ATG ACA 528 Ala Ser Leu Tyr Ser Phe Pro Glu Pro Glu Ala Ala Gin Pro Met Thr 165 170 175 AAG AAG CGA AAA GTA GAT GGT TTG AGC ACA GAG GCA GAG CAG CCC TTC 576 Lys Lys Arg Lys Val Asp Gly Leu Ser Thr Glu Ala Glu Gin Pro Phe 180 185 190 ATT CCA GTA GAG GTG CTC GTA GAC CTG TTC CTC AAG GAA GGT GCC TGT 624 He Pro Val Glu Val Leu Val Asp Leu Phe Leu Lys Glu Gly Ala Cys 195 200 205 GAT GAA TTG TTC TCC TAC CTC ATT GAG AGA GTG AAG CGA AAG AAA AAT 672 Asp Glu Leu Phe Ser Tyr Leu He Glu Arg Val Lys Arg Lys Lys Asn 210 215 220 GTA CTA CGG CTG TGC TGT AAG AAG CTG AAG ATT TTT GCA ATG CCC ATG 720 Val Leu Arg Leu Cys Cys Lys Lys Leu Lys He Phe Ala Met Pro Met 225 230 235 240 CAG GAT ATC AAG ATG ATC CTG AAA ATG GTG CAG CTG GAC TCT ATT GAA 768 Gin Asp He Lys Met He Leu Lys Met Val Gin Leu Asp Ser He Glu 245 250 255 GAT TTG GAA GTG ACT TGT ACC TGG AAG CTA CCC ACC TTG GCG AAA TTT 816 Asp Leu Glu Val Thr Cys Thr Trp Lys Leu Pro Thr Leu Ala Lys Phe 260 265 270 TCT CCT TAC CTG GGC CAG ATG ATT AAT CTG CGT AGA CTC CTC CTC TCC 864 Ser Pro Tyr Leu Gly Gin Met He Asn Leu Arg Arg Leu Leu Leu Ser 275 280 285 CAC ATC CAT GCA TCT TCC TAC ATT TCC CCG GAG AAG GAA GAG AGT ATA 912 His He His Ala Ser Ser Tyr He Ser Pro Glu Lys Glu Glu Ser He 290 295 300 TCG CCC AGT TCA CCT CTC AGT TCC TCA GTC TGC AGT GCC TGC AGG CTC 960 Ser Pro Ser Ser Pro Leu Ser Ser Ser Val Cys Ser Ala Cys Arg Leu 305 310 315 320 TCT ATG TGG ACT CTT TAT TTT TCC TTA GAG GCC GCC TGG ACT CAG TTG 1008 Ser Met Trp Thr Leu Tyr Phe Ser Leu Glu Ala Ala Trp Thr Gin Leu 325 330 335 CTC AGG CAC GTG ATG AAC CCC TTG GAA ACC CTC TCA ATA ACT AAC TGC 1056 Leu Arg His Val Met Asn Phe Leu Glu Thr Leu Ser He Thr Asn Cys 340 345 350 CGG CTT TCG GAA GGG GAT GTG ATG CAT CTG TCC CAG AGT CCC AGC GTC 1104 Arg Leu Ser Glu Gly Asp Val Met His Leu Ser Gin Ser Pro Ser Val 355 360 365 AGT CAG CTA AGT GTC CTG AGT CTA AGT GGG GTC ATG CTG ACC GAT GTA 1152 Ser Gin Leu Ser Val Leu Ser Leu Ser Gly Val Met Leu Thr Asp Val 370 375 380 AGT CCC GAG CCC CTC CAA GCT CTG CTG GAG AGA GCC TCT GCC ACC CTC 1200 Ser Pro Glu Pro Leu Gin Ala Leu Leu Glu Arg Ala Ser Ala Thr Leu 385 390 395 400 CAG GAC CTG GTC TTT GAT GAG TGT GGG ATC ACG GAT GAT CAG CTC CTT 1248 Gin Asp Leu Val Phe Asp Glu Cys Gly He Thr Asp Asp Gin Leu Leu 405 410 415 GCC CTC CTG CCT TCC CTG AGC CAC TGC TCC CAG CTT ACA ACC TTA AGC 1296 Ala Leu Leu Pro Ser Leu Ser His Cys Ser Gin Leu Thr Thr Leu Ser 420 425 430 TTC TAC GGG AAT TCC ATC TCC ATA TCT GCC TTG CAG AGT CTC CTG CAG 1344 Phe Tyr Gly Asn Ser He Ser He Ser Ala Leu Gin Ser Leu Leu Gin 435 440 445 CAC CTC ATC GGG CTG AGC AAT CTG ACC CAC GTG CTG TAT CCT GTC CCC 1392 His Leu He Gly Leu Ser Asn Leu Thr His Val Leu Tyr Pro Val Pro 450 455 460 CTG GAG AGT TAT GAG GAC ATC CAT GGT ACC CTC CAC CTG GAG AGG CTT 1440 Leu Glu Ser Tyr Glu Asp He His Gly Thr Leu His Leu Glu Arg Leu 465 470 475 480 GCC TAT CTG CAT GCC AGG CTC AGG GAG TTG CTG TGT GAG TTG GGG CGG 1488 Ala Tyr Leu His Ala Arg Leu Arg Glu Leu Leu Cys Glu Leu Gly Arg 485 490 495 CCC AGC ATG GTC TGG CTT AGT GCA ACC CCT GTC CTC ACT GTG GGG ACA 1536 Pro Ser Met Val Trp Leu Ser Ala Thr Pro Val Leu Thr Val Gly Thr 500 505 510 GAA CCT TCT ATG ACC CGG 1554 Glu Pro Ser Met Thr Arg 515

Claims: We claim: 1. Composition of matter comprising: (i) a tumor rejection antigen precursor or a tumor rejection antigen, and at least one of: (ii) a pharmaceutically acceptable adjuvant, and a T or B cell growth factor. 2. The composition of matter of claim 1, wherein said tumor rejection antigen precursor is a MAGE protein. 3. The composition of matter of claim 1, wherein said tumor rejection antigen precursor is a BAGE protein. 4. The composition of matter of claim 1, wherein said tumor rejection antigen precursor is a GAGE protein. 5. The composition of claim 1, wherein said tumor rejection antigen is derived from a MAGE protein. 6. The composition of matter of claim 5, wherein said MAGE protein is MAGE-1, MAGE-2, or MAGE-3. 7. The composition of matter of claim 6, wherein said tumor rejection antigen consists of one of SEQ ID NO: 1 through SEQ ID NO: 5. 8. The composition of matter of claim 1, wherein said pharmaceutically acceptable adjuvant is a substantially pure saponin derived from Quillaia saponaria. 9. The composition of matter of claim 8, wherein said substantially pure saponin is selected from the group consisting of QA-7, QA-21, QA-17, and QA-18. 10. The composition of matter of claim l, wherein said pharmaceutically acceptable adjuvant is MTP-MF59. 11. Method for stimulating an immune response in a subject comprising administering the composition of matter of claim 1 to said subject in an amount sufficient to provoke an immune response to said tumor rejection antigen precursor or tumor rejection antigen. 12. The method of claim 11, wherein said immune response comprises proliferation of T cells specific for complexes of said tumor rejection antigen and a major histocompatibility complex molecule to which said tumor rejection antigen binds. 13. The method of claim 11, wherein said T cells are cytolytic T cells. 14. The method of claim 11, wherein said immune response comprises production of antibodies against said tumor rejection antigen precursor or tumor rejection antigen. 15. The composition of claim l, in intravenous form. 16. The composition of claim 1, in the form of a liposome.

Inventors: BOON-FALLEUR THIERRY, VAN DEN EYNDE BENOIT, VAN DER BRUGGEN PIERRE, BOON-FALLEUR, THIERRY, VAN DEN EYNDE, BENOIT, VAN DER BRUGGEN, PIERRE
Applicants: LUDWIG INST CANCER RES, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 1995
Main classification: A61K38
IPC codes: A61K9, A61K38, A61K39, A61P37, C07K14